Albumin binding antibodies and uses thereof

By binding to albumin monodomain antibodies in anti-albumin constructs to albumin, the serum half-life of therapeutic agents is extended, the frequent administration of existing therapeutic agents and side effects are solved, and the therapeutic effect and patient compliance are improved .

CN113508134BActive Publication Date: 2024-12-03ANWITA BIOSCIENCES INC
View PDF 56 Cites 0 Cited by

Patent Information

Application Number
CN202080015296.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-22
Filing Date
2020-02-21
Publication Date
2024-12-03
Estimated Expiration
2040-02-21

AI Technical Summary

Technical Problem

Due to the short serum half-life of existing therapeutic agents, frequent systemic administration, causing adverse side effects and high medical costs, and it is difficult to maintain therapeutic effects.

Method used

Develop anti-albumin constructs containing anti-albumin single domain antibody (sdAb) moieties to prolong serum half-life by binding to albumin, reduce the frequency of dosing and reduce side effects.

Benefits of technology

It extends the serum half-life of the therapeutic agent, reduces the frequency of administration and side effects, improves patient compliance and reduces medical costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113508134B_ABST
    Figure CN113508134B_ABST
Patent Text Reader

Abstract

The present disclosure provides anti-albumin constructs, each of which comprises an anti-albumin single domain antibody (sdAb) portion. The anti-albumin constructs may also comprise a therapeutic agent, such as an antigen binding portion or a cytokine. The present disclosure also provides methods for preparing and using the anti-albumin constructs.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 809,475, filed on February 22, 2019, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure relates to anti-albumin constructs comprising an anti-albumin single domain antibody (sdAb) portion and methods for their preparation and use.

[0004] Sequence Listing Reference

[0005] This specification is submitted together with a sequence listing in computer readable form (CRF) named 216A003WO01_SEQLIST_ST25.txt with a byte size of 117,812 created on February 21, 2020, the contents of which are incorporated herein by reference in their entirety. Background Art

[0006] Due to the short serum half-life, many therapeutic agents, especially biological products such as peptides, polypeptides and polynucleotides, have limited applications. Due to the short serum half-life, some therapeutic agents cannot achieve the desired efficacy. And some therapeutic agents must be administered at high frequency and / or higher doses in order to maintain the serum level required for the therapeutic effect. Frequent systemic administration of such therapeutic agents is usually accompanied by adverse side effects. For example, especially when the therapeutic agent is administered intravenously, the patient shows considerable discomfort to frequent systemic injections, the risk of infection associated with administration is high, and hospitalization or frequent visits to the hospital may be required. In addition, in long-term treatment, daily intravenous injections can produce considerable side effects, such as tissue scarring and vascular lesions caused by repeated puncture of blood vessels. Similar problems are known for all frequently administered systemic therapeutic agents, for example, insulin is administered to diabetic patients or interferon drugs are administered to multiple sclerosis patients. All of these factors will lead to a decrease in patient compliance and an increase in medical system costs. Therefore, it is necessary to develop therapeutic agents with extended serum half-life. Summary of the invention

[0007] The present disclosure provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin single domain antibody (sdAb) portion that binds to albumin, wherein the sdAb portion comprises: a CDR1 comprising an amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135, or 138, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139, or a variant thereof comprising up to about 3 amino acid substitutions; A CDR3 of the amino acid sequence of NO:12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140, or a variant thereof comprising up to about 3 amino acid substitutions.

[0008] The present disclosure also provides an anti-albumin construct comprising a first polypeptide portion, the first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises: a CDR1 comprising an amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135, or 138; a CDR2 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139. NO:12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region.

[0009] The present disclosure also provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150.

[0010] The present disclosure also provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, and 105-115.

[0011] The present disclosure provides an isolated anti-albumin construct comprising a first polypeptide portion, which comprises an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes CDR1, CDR2 and CDR3, which CDR1, CDR2 and CDR3 respectively comprise the amino acid sequences of CDR1, CDR2 and CDR3 within a heavy chain variable domain, and the heavy chain variable domain has a sequence shown in any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150.

[0012] The present disclosure provides an isolated anti-albumin construct comprising a first polypeptide portion, which comprises an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes CDR1, CDR2 and CDR3, which CDR1, CDR2 and CDR3 respectively comprise the amino acid sequences of CDR1, CDR2 and CDR3 within a heavy chain variable domain, and the heavy chain variable domain has a sequence shown in any one of SEQ ID NOs: 1-9, 45-53 and 105-115.

[0013] In certain embodiments, according to any of the above constructs, the sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150; H H domain, or a variant thereof having at least about 80% sequence identity to any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150. In certain embodiments, the sdAb portion comprises: a V domain comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150; H H domain, or its V H Variants containing up to about 3 amino acid substitutions in the H domain.

[0014] In certain embodiments, according to any of the above constructs, the sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53 and 105-115; HH domain, or a variant thereof having at least about 80% sequence identity with any one of SEQ ID NOs: 1-9, 45-53, and 105-115. In certain embodiments, the sdAb portion comprises: a V domain comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, and 105-115; H H domain, or its V H Variants containing up to about 3 amino acid substitutions in the H domain.

[0015] The present disclosure provides an isolated anti-albumin construct comprising a first polypeptide comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes: a CDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 31 and 34, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 11, 14, 17, 20, 23, 26, 29, 32 and 35, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 12, 15, 18, 21, 24, 27, 30, 33 and 36, or a variant thereof comprising up to about 3 amino acid substitutions.

[0016] In certain embodiments, according to any of the above constructs, the sdAb portion includes: a CDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 31 and 34; a CDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 11, 14, 17, 20, 23, 26, 29, 32 and 35; and a CDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 12, 15, 18, 21, 24, 27, 30, 33 and 36; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region.

[0017] In certain embodiments, according to any of the above constructs, the sdAb portion includes: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or a variant thereof comprising up to about 3 amino acid substitutions; (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 13, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15, or a variant thereof comprising up to about 3 amino acid substitutions; (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 16, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18. NO:17, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:18, or a variant thereof comprising up to about 3 amino acid substitutions; (4) a CDR1 comprising the amino acid sequence of SEQ ID NO:19, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:20, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:21, or a variant thereof comprising up to about 3 amino acid substitutions; (5) a CDR1 comprising the amino acid sequence of SEQ ID NO:22, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:23, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:24, or a variant thereof comprising up to about 3 amino acid substitutions; (6) a CDR1 comprising the amino acid sequence of SEQ ID NO:25, or a variant thereof comprising up to about 3 amino acid substitutions; NO:25, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:26, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:27, or a variant thereof comprising up to about 3 amino acid substitutions; (7) a CDR1 comprising the amino acid sequence of SEQ ID NO:28, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:29, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:30, or a variant thereof comprising up to about 3 amino acid substitutions;(8) a CDR1 comprising the amino acid sequence of SEQ ID NO:31, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:32, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:33, or a variant thereof comprising up to about 3 amino acid substitutions; or (9) a CDR1 comprising the amino acid sequence of SEQ ID NO:34, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:35, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:36, or a variant thereof comprising up to about 3 amino acid substitutions. ;

[0018] In certain embodiments, according to any of the above constructs, the sdAb portion comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 16, a CDR2 comprising the amino acid sequence of SEQ ID NO: 17, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 19, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; NO:20, and a CDR2 comprising the amino acid sequence of SEQ ID NO:21, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (5) a CDR1 comprising the amino acid sequence of SEQ ID NO:22, a CDR2 comprising the amino acid sequence of SEQ ID NO:23, and a CDR3 comprising the amino acid sequence of SEQ ID NO:24, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (6) a CDR1 comprising the amino acid sequence of SEQ ID NO:25, a CDR2 comprising the amino acid sequence of SEQ ID NO:26, and a CDR3 comprising the amino acid sequence of SEQ ID NO:27, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (7) a CDR1 comprising the amino acid sequence of SEQ ID NO:28, a CDR2 comprising the amino acid sequence of SEQ ID NO:29, and a CDR3 comprising the amino acid sequence of SEQ ID NO:30, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (8) a CDR1 comprising the amino acid sequence of SEQ ID NO:29, and a CDR3 comprising the amino acid sequence of SEQ ID NO:30, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; NO:31, a CDR2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR3 comprising the amino acid sequence of SEQ ID NO:33, or variants thereof comprising up to about 3 amino acid substitutions in the CDR region; or (9) a CDR1 comprising the amino acid sequence of SEQ ID NO:34, a CDR2 comprising the amino acid sequence of SEQ ID NO:35, and a CDR3 comprising the amino acid sequence of SEQ ID NO:36, or variants thereof comprising up to about 3 amino acid substitutions in the CDR region.

[0019] The present disclosure provides an anti-albumin construct comprising a first polypeptide comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53.

[0020] The present disclosure provides an isolated anti-albumin construct comprising a first polypeptide comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes CDR1, CDR2 and CDR3, and the CDR1, CDR2 and CDR3 respectively comprise the amino acid sequences of CDR1, CDR2 and CDR3 within a heavy chain variable domain, and the heavy chain variable domain has a sequence shown in any one of SEQ ID NOs: 1-9 and 45-53.

[0021] In certain embodiments, according to any of the above constructs, the sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain, or a variant thereof having at least about 80% sequence identity to any one of SEQ ID NOs: 1-9 and 45-53. In certain embodiments, the sdAb portion comprises: a V domain comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain, or its V H Variants containing up to about 3 amino acid substitutions in the H domain.

[0022] The present disclosure provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes: a CDR1 comprising an amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising an amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140, or a variant thereof comprising up to about 3 amino acid substitutions.

[0023] In certain embodiments, according to any of the constructs described herein, the sdAb portion comprises: a CDR1 comprising an amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising an amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR regions.

[0024] In certain embodiments, according to any of the constructs described herein, the sdAb portion comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 116, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117, or a variant thereof comprising up to about 3 amino acid substitutions; (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 118, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 119, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 120, or a variant thereof comprising up to about 3 amino acid substitutions; (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122, or a variant thereof comprising up to about 3 amino acid substitutions; NO:122, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO:123, or a variant thereof comprising up to about 3 amino acid substitutions; (4) a CDR1 comprising an amino acid sequence of SEQ ID NO:124, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising an amino acid sequence of SEQ ID NO:125, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO:126, or a variant thereof comprising up to about 3 amino acid substitutions; (5) a CDR1 comprising an amino acid sequence of SEQ ID NO:121, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising an amino acid sequence of SEQ ID NO:127, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO:128, or a variant thereof comprising up to about 3 amino acid substitutions; (6) a CDR1 comprising an amino acid sequence of SEQ ID NO:124, or a variant thereof comprising up to about 3 amino acid substitutions; NO:129, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:130, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:131, or a variant thereof comprising up to about 3 amino acid substitutions; (7) a CDR1 comprising the amino acid sequence of SEQ ID NO:132, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:133, or a variant thereof comprising up to about 3 amino acid substitutions;and a CDR3 comprising the amino acid sequence of SEQ ID NO: 134, or a variant thereof comprising up to about 3 amino acid substitutions; (8) a CDR1 comprising the amino acid sequence of SEQ ID NO: 135, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 136, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 137, or a variant thereof comprising up to about 3 amino acid substitutions; or (9) a CDR1 comprising the amino acid sequence of SEQ ID NO: 138, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 139, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 140, or a variant thereof comprising up to about 3 amino acid substitutions. ;

[0025] In certain embodiments, according to any of the constructs described herein, the sdAb portion comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 116, a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 118, a CDR2 comprising the amino acid sequence of SEQ ID NO: 119, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 120; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, a CDR2 comprising the amino acid sequence of SEQ ID NO: 122, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 124, a CDR2 comprising the amino acid sequence of SEQ ID NO: 125, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 126; (5) a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, a CDR2 comprising the amino acid sequence of SEQ ID NO: 127, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 128; or a variant thereof comprising at most about 3 amino acid substitutions in the CDR region; (6) a CDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 131; or a variant thereof comprising at most about 3 amino acid substitutions in the CDR region; (7) a CDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CDR3 comprising the amino acid sequence of SEQ ID NO: NO: 134; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; (8) a CDR1 comprising the amino acid sequence of SEQ ID NO: 135, a CDR2 comprising the amino acid sequence of SEQ ID NO: 136, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 137; or a variant thereof comprising up to about 3 amino acid substitutions in the CDR region; or (9) a CDR1 comprising the amino acid sequence of SEQ ID NO: 138, a CDR2 comprising the amino acid sequence of SEQ ID NO: 139, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 140;or a variant thereof comprising up to about 3 amino acid substitutions in the CDR regions. ;

[0026] The present disclosure provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 99-101, 103-115, 149 and 150.

[0027] The present disclosure provides an anti-albumin construct comprising a first polypeptide portion comprising an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 105-115.

[0028] The present disclosure provides an isolated anti-albumin construct comprising a first polypeptide portion, which comprises an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes CDR1, CDR2 and CDR3, which CDR1, CDR2 and CDR3 respectively comprise the amino acid sequences of CDR1, CDR2 and CDR3 within a heavy chain variable domain, and the heavy chain variable domain has a sequence shown in any one of SEQ ID NOs: 99-101, 103-115, 149 and 150.

[0029] The present disclosure provides an isolated anti-albumin construct, comprising a first polypeptide portion, which comprises an anti-albumin sdAb portion that binds to albumin, wherein the sdAb portion includes CDR1, CDR2, and CDR3, and the CDR1, CDR2, and CDR3 respectively comprise the amino acid sequences of CDR1, CDR2, and CDR3 within a heavy chain variable domain, and the heavy chain variable domain has a sequence shown in any one of SEQ ID NOs: 105-115.

[0030] In certain embodiments, according to any of the constructs described herein, the sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 99-101, 103-115, 149 and 150; H H domain, or a variant thereof having at least about 80% sequence identity to any one of SEQ ID NOs: 99-101, 103-115, 149 and 150. In certain embodiments, the sdAb portion comprises: a V domain comprising the amino acid sequence of any one of SEQ ID NOs: 99-101, 103-115, 149 and 150; H H domain, or its V HVariants containing up to about 3 amino acid substitutions in the H domain.

[0031] In certain embodiments, according to any of the constructs described herein, the sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain, or a variant thereof having at least about 80% sequence identity to any one of SEQ ID NOs: 105-115. In certain embodiments, the sdAb portion comprises: a V domain comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain, or its V H Variants containing up to about 3 amino acid substitutions in the H domain.

[0032] In certain embodiments, according to any of the constructs described above, the albumin is human serum albumin (HSA), rhesus serum albumin (RhsA), cynomolgus serum albumin (CySA) or murine serum albumin (MuSA). In certain embodiments, the albumin is human serum albumin.

[0033] In certain embodiments, according to any of the above constructs, the construct is about 10 -6 M to about 10 -10 K in the M range D In certain embodiments, the construct is present at about 10 -6 M to about 10 -8 K in the M range D Binds to albumin.

[0034] In certain embodiments, according to any of the above constructs, the construct is at a pH of about 7 at about 10 -6 M to about 10 -10 K in the M range D In certain embodiments, the construct binds to albumin at a pH of about 7 at about 10 -6 M to about 10 -8 K in the M range D Binds to albumin.

[0035] In certain embodiments, according to any of the above constructs, the construct is at a pH of about 5.5 at about 10 -6 M to about 10 -10 K in the M range D In certain embodiments, the construct binds to albumin at a pH of about 5.5 at about 10 -6 M to about 10 -8 K in the M rangeD Binds to albumin.

[0036] In certain embodiments, according to any of the above constructs, the portion of the sdAb that binds to albumin is camelid, chimeric, human, partially humanized or fully humanized.

[0037] In certain embodiments, according to any one of the constructs in the above constructs, the construct further comprises a second polypeptide fused to the first polypeptide. In certain embodiments, the second polypeptide is fused to the amino terminus (N-terminus) of the first polypeptide. In certain embodiments, the second polypeptide is fused to the carboxyl terminus (C-terminus) of the first polypeptide. In certain embodiments, the second polypeptide is fused to the first polypeptide via a first joint. In certain embodiments, the first joint is cleavable. In certain embodiments, the first joint is not cleavable. In certain embodiments, the construct further comprises a third polypeptide fused to the first polypeptide and / or the second polypeptide. In certain embodiments, the third polypeptide is fused to the first polypeptide or the second polypeptide via a second joint. In certain embodiments, the second joint is cleavable. In certain embodiments, the second joint is not cleavable. In certain embodiments, the second polypeptide and / or the third polypeptide comprise an antigen binding portion. In certain embodiments, the antigen binding portion binds to a tumor antigen. In certain embodiments, the tumor antigen is selected from mesothelin (MSLN), GPA33, Her-2, EGFR and CD20. In certain embodiments, the tumor antigen is selected from CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA and BCMA. In certain embodiments, the second polypeptide and / or the third polypeptide comprises a cytokine. In certain embodiments, the cytokine is selected from IL-21, IL-7, IL-15, IL-15 bound to IL-15Rα or a fragment thereof, IL-33 and IL-22.

[0038] In certain embodiments, according to any of the above constructs, the construct further comprises a signal peptide.

[0039] In certain embodiments, according to any of the above constructs, the serum half-life of the second polypeptide and / or the third polypeptide in the construct is at least 3 times longer than the second polypeptide and / or the third polypeptide in the absence of the anti-albumin sdAb portion.

[0040] The present disclosure provides a pharmaceutical composition comprising any one of the above constructs.

[0041] The present disclosure provides a method of treating a disease or condition in an individual, comprising administering to the individual an effective amount of any one of the constructs or compositions described above. In certain embodiments, the individual is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 ADCC activity of NK cells against N87 cells in the presence of: (i) recombinant human IL-21 (rhIL-21) (30 ng / mL), (ii) mouse IL-21-anti-HSA construct C1 (SEQ ID NO:99) (60 ng / mL), (iii) human IL-21 anti-HSA construct C2 (SEQ ID NO:100) (60 ng / mL) or (iv) a combination of rhIL-15C5 (SEQ ID NO:102) / hIL-15Rα-anti-HSA construct C6 (SEQ ID NO:103) (60 ng / mL); and in the presence of 0.2 ng / mL, 2 ng / mL, 20 ng / mL or 200 ng / mL of anti-mesothelin antibody B1, wherein antibody B1 comprises CDR1 of SEQ ID NO:92, CDR2 of SEQ ID NO:93, and CDR3 of SEQ ID NO:94.

[0043] Figure 2 The ADCC activity of NK cells against H226 cells in the presence of: (i) rhIL-21 (30 ng / mL), (ii) mIL-21-anti-HSA construct C1 (60 ng / mL), (iii) hIL-21-anti-HSA construct C2 (60 ng / mL) or (iv) a combination of rhIL-15C5 / hIL-15Rα-anti-HSA construct C6 (60 ng / mL); and 0.2 ng / mL, 2 ng / mL, 20 ng / mL or 200 ng / mL of anti-mesothelin antibody B1 is shown.

[0044] Figure 3 Shown are the ADCC activity of NK cells against N87 cells in the presence of different concentrations of (i) recombinant human IL-15 (rhIL-15), (ii) mIL-21-anti-HSA construct C1, (iii) hIL-21-anti-HSA construct C2, (iv) a combination of rhIL-15C5 / hIL-15Rα-anti-HSA construct C6, or (v) a combination of rhIL-15C5 / hIL-15Rα-anti-HSA construct C7 (SEQ ID NO: 104); and 3 ng / mL of anti-mesothelin antibody B1.

[0045] Figure 4Shown are the ADCC activity of NK cells against H226 cells in the presence of different concentrations of (i) rhIL-15 (rhIL-15), (ii) mIL-21-anti-HSA construct C1, (iii) hIL-21-anti-HSA construct C2, (iv) a combination of rhIL-15C5 / hIL-15Rα-anti-HSA construct C6, or (v) a combination of rhIL-15C5 / hIL-15Rα-anti-HSA construct C7 (SEQ ID NO: 104); and 20 ng / mL of anti-mesothelin antibody B1.

[0046] Figure 5 The anti-tumor activity of the mIL-21-anti-HSA construct C1 in the presence or absence of anti-mouse PD-1 antibody in the MC38 syngeneic mouse model is shown.

[0047] Figure 6 Shown is the pharmacokinetic profile of the hIL-21-anti-HSA construct C2 in mice.

[0048] Figure 7 Pharmacokinetic profiles of hIL-21-anti-HSA construct C3 (SEQ ID NO: 149) and hIL-21-anti-HSA construct C4 (SEQ ID NO: 150) are shown. DETAILED DESCRIPTION

[0049] The present disclosure relates to anti-albumin constructs comprising anti-albumin sdAbs and methods of making and using the same for treating a disease or disorder.

[0050] Thus, one aspect of the present disclosure provides an anti-albumin construct comprising an anti-albumin sdAb portion. In certain embodiments, the anti-albumin construct comprises a second polypeptide. In certain embodiments, the second polypeptide comprises a therapeutic agent, such as a cytokine or an antigen binding portion that binds to a tumor antigen.

[0051] Also provided are compositions (such as pharmaceutical compositions), kits, and articles of manufacture, each comprising an anti-albumin construct described herein; and methods of making and using the anti-albumin constructs described herein to treat a disease or disorder (such as cancer).

[0052] In addition, compositions, kits, and articles of manufacture are provided, each comprising the bispecific antibodies described herein; and methods for their preparation and use.

[0053] I. Definitions

[0054] To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.

[0055] Generally, the nomenclature used herein and the laboratory procedures in biochemistry, biology, molecular biology, cell biology, immunology and pharmacology described herein are those well known and commonly used in the art. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0056] The terms "anti-albumin construct" and "anti-albumin protein" are used interchangeably herein, eg, to refer to a polypeptide that specifically binds to albumin.

[0057] An "isolated" antibody or construct is one that has been identified, separated and / or recovered from a component of its (e.g., natural or recombinant) production environment. Preferably, an isolated antibody or construct is free from substantially all other components of its production environment. Contaminating components of the production environment of an isolated antibody or construct, such as those produced by recombinant transfected cells, are substances that would normally interfere with the research, diagnostic or therapeutic use of the antibody or construct, and may include enzymes, hormones and other proteinaceous or non-proteinaceous substances. In preferred embodiments, the antibody or construct is purified to: (1) greater than 95% by weight of the antibody or construct, in certain embodiments, greater than 99% by weight of the antibody or construct; (2) sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence using a spinning cup sequencer; or (3) confirmed to be homogeneous by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or silver staining. An isolated antibody or construct includes an antibody in situ within a recombinant cell, since at least one component of the antibody's natural environment is not present. Typically, however, an isolated antibody or construct is prepared by at least one purification step.

[0058] A full-length antibody consists of two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable domains of the heavy and light chains are referred to as “V H ” and “V LThe variable regions in both chains typically contain three highly variable loops, termed complementarity determining regions (CDRs) (light chain (LC) CDRs, including LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC) CDRs, including HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibodies and antigen-binding fragments disclosed herein may be defined or delineated according to the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDRs of the heavy or light chain are inserted between flanking extensions called framework regions (FRs), which are more highly conserved than the CDRs and form a scaffold to support the hypervariable loops. The constant regions of the heavy and light chains do not participate in antigen binding, but exhibit various effector functions. Antibodies are classified based on the amino acid sequence of their heavy chain constant regions. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several major antibody classes are divided into subclasses, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain).

[0059] The terms "full-length antibody", "intact antibody" or "whole antibody" are used interchangeably to refer to an antibody in substantially complete form, as opposed to an antibody fragment. Specifically, a full-length 4-chain antibody includes an antibody having a heavy chain and a light chain containing an Fc region. A full-length heavy chain antibody includes a heavy chain variable domain (such as a V H F) and Fc region. The constant domain may be a native sequence constant domain (e.g., a human native sequence constant domain) or an amino acid sequence variant thereof. In some cases, a complete antibody may have one or more effector functions.

[0060] The "variable region" or "variable domain" of an antibody refers to the amino terminal domain of the heavy chain or light chain of an antibody. The variable domains of the heavy chain and light chain can be referred to as "V H ” and “V L These domains are usually the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen-binding site. Only heavy chain antibodies from species of the family Camelidae have a single heavy chain variable region, called a "V H H". Therefore V H H is a special type of V H .

[0061] As used herein, the term "antigen-binding fragment" refers to an antibody fragment, including, for example, diabodies, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (dsdiabodies), single-chain Fv (scFv), scFv dimers (divalent diabodies), multispecific antibodies formed from a portion of an antibody including one or more CDRs, camelized single domain antibodies, nanobodies, domain antibodies, bivalent domain antibodies, or any other antibody fragment that binds to an antigen but does not include a complete antibody structure. An antigen-binding fragment is capable of binding to the same antigen to which a parent antibody or parent antibody fragment (e.g., parent scFv) binds. In certain embodiments, an antigen-binding fragment includes one or more CDRs from a specific human antibody and grafted to the framework region of one or more different human antibodies.

[0062] The term "Fv" refers to the smallest antibody fragment that contains a complete antigen recognition and antigen binding site. This fragment consists of a dimer of a heavy chain variable region domain and a light chain variable region domain in tight and non-covalent association. These two domains fold to produce six hypervariable loops (3 loops each for the heavy chain and light chain), which contribute amino acid residues for antigen binding and give the antibody antigen binding specificity. However, even a single variable domain (or half an Fv that includes only three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, but the affinity is lower than that of the entire binding site.

[0063] The term "single-chain Fv", "sFv" or "scFv" refers to a fragment of a polypeptide chain comprising V H and V L In certain embodiments, the scFv polypeptide further comprises a V H and V L The polypeptide linker between the domains allows the scFv to form the desired structure for antigen binding. See Plückthun, The Pharmacology of Monoclonal Antibodies, Rosenburg and Moore, eds., Springer-Verlag, New York, Vol. 113, pp. 269-315 (1994).

[0064] The term "heavy chain antibody" or "HCAb" refers to a functional antibody comprising a heavy chain but lacking the light chain typically present in a 4-chain antibody. Camelids (such as camels, llamas or alpacas) are known to produce HCAbs.

[0065] The term "single domain antibody" or "sdAb" refers to a single antigen-binding polypeptide having three complementary determining regions (CDRs). An sdAb is capable of binding to an antigen alone without pairing with a corresponding CDR-containing polypeptide. In some cases, a single domain antibody is engineered from a camelid HCAb, and its heavy chain variable domain is referred to herein as a "V H H" (the variable domain of the heavy chain of a heavy chain antibody). Camelid sdAbs are one of the smallest known antigen-binding antibody fragments. See, e.g., Hamers-Casterman et al., Nature, Vol. 363: 446-448 (1993); Greenberg et al., Nature, Vol. 374: 168-173 (1995); Hassanzadeh-Ghassabeh et al., Nanomedicine (Lond.), Vol. 8: 1013-1026 (2013). The basic V H H has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1 to FR4 refer to framework regions 1 to 4, respectively, and wherein CDR1 to CDR3 refer to complementarity determining regions 1 to 3, respectively.

[0066] The term "hypervariable region", "HVR" or "HV" refers to a region of an antibody variable domain that is highly variable in sequence and / or forms a structurally defined loop. Typically, a single domain antibody includes three HVRs (or CDRs): HVR1 (or CDR1), HVR2 (or CDR2) and HVR3 (or CDR3). HVR3 (or CDR3) is the most diverse of the three HVRs and is believed to play a unique role in conferring fine specificity to antibodies. See, e.g., Hamers-Casterman et al., Nature, Vol. 363: pp. 446-448 (1993); Sheriff et al., Nature Struct. Biol., Vol. 3: pp. 733-736 (1996).

[0067] The term "CDR" or "complementarity determining region" refers to the non-contiguous antigen binding sites found within the variable regions of heavy and light chain polypeptides. These specific regions have been described by the following journals: Kabat et al., J. Biol. Chem., Vol. 252: 6609-6616 (1977); Kabat et al., U.S. Department of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol., Vol. 196: 901-917 (1987); Al-Lazikani et al., J. Biol., Vol. 197: 901-917 (1987); B. et al., J. Mol. Biol., Vol. 273: pp. 927-948 (1997); MacCallum et al., J. Mol. Biol., Vol. 262: pp. 732-745 (1996); Abhinandan and Martin, Mol. Immunol., Vol. 45: pp. 3832-3839 (2008); Lefranc et al., Dev. Comp. Immunol., Vol. 27: pp. 55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., Vol. 309: pp. 657-670 (2001); wherein the definitions include amino acid residues or subsets of amino acid residues that overlap when compared to each other. However, the application of any definition when referring to the CDRs of an antibody or grafted antibody or variant thereof is within the scope of the term as defined and used herein. The amino acid residues covering the CDRs defined by each of the references cited above are listed in Table 1 below for comparison. CDR prediction algorithms and interfaces are known in the art, including, for example, Abhinandan and Martin, Mol. Immunol., Vol. 45: 3832-3839 (2008); Ehrenmann et al., Nucleic Acids Res., Vol. 38: D301-D307 (2010); Adolf-Bryfogle et al., Nucleic Acids Res., Vol. 43: D432-D438 (2015).

[0068] Table 1. CDR definitions

[0069]

[0070] 1 The residue numbering follows the nomenclature of Kabat et al. (see above)

[0071] 2 The residue numbering follows the nomenclature of Chothia et al. (see above)

[0072] 3 The residue numbering follows the nomenclature of MacCallum et al. (see above)

[0073] 4 The residue numbering follows the nomenclature of Lefranc et al. (see above)

[0074] 5 The residue numbering follows the nomenclature of Honegger and Plückthun (see above)

[0075] The expressions "variable domain residues are numbered according to Kabat" or "amino acid positions are numbered according to Kabat" and variations thereof refer to the use of the numbering system of Kabat et al. (see above) for compiling heavy chain variable domains or light chain variable domains for antibodies. Using this numbering system, the actual linear amino acid sequence may contain fewer or more amino acids, corresponding to a shortening or insertion of a variable domain FR or HVR. For example, a heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to the Kabat system) and an inserted residue after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c, etc., according to the Kabat system). The Kabat residue numbering for a given antibody can be determined by aligning the antibody sequence with the "standard" Kabat numbering sequence for regions of homology.

[0076] Unless otherwise indicated, the numbering of residues in immunoglobulin heavy chains herein refers to the EU index numbering of Kabat et al. (supra). "EU index as of Kabat" refers to the residue numbering of the human IgG1 EU antibody.

[0077] "Framework" or "FR" residues are those variable domain residues other than the CDR residues as herein defined.

[0078] The "humanized" form of non-human (e.g., rodent) antibodies is a chimeric antibody, each of which contains the least sequence of non-human antibody sources. For the most part, humanized antibodies are human immunoglobulins (receptor antibodies), wherein residues from receptor hypervariable regions (HVRs) are replaced by residues from hypervariable regions of non-human species (donor antibodies), non-human species such as mice, rats, rabbits, or non-human primates, and the hypervariable regions of these species have the desired antibody specificity and affinity. In certain embodiments, certain framework regions (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. In certain embodiments, humanized antibodies may include residues that are not present in receptor antibodies or donor antibodies. In certain embodiments, humanized antibodies include substantially all of at least one (e.g., two) variable domains, wherein all or substantially all of the hypervariable loops in each variable domain correspond to the hypervariable loops of non-human immunoglobulins, and all or substantially all of the FRs are FRs of human immunoglobulin sequences. In certain embodiments, humanized antibodies also include at least a portion of an immunoglobulin constant region (Fc), such as human immunoglobulin Fc. See Jones et al., Nature, Vol. 321: pp. 522-525 (1986); Riechmann et al., Nature, Vol. 332: pp. 323-329 (1988); Presta, Curr. Op. Struct. Biol., Vol. 2: pp. 593-596 (1992).

[0079] The term "percent (%) amino acid sequence identity" refers to the percentage of amino acid residues in a candidate antibody or construct that are identical to the amino acid residues in the antibody or construct being compared. In certain embodiments, % amino acid sequence identity values ​​are determined using the sequence comparison computer program MUSCLE. Edgar, Nucleic Acids Res., Vol. 32: pp. 1792-1797 (2004); Edgar, BMC Bioinformatics, Vol. 5: p. 113 (2004).

[0080] The term "constant domain" refers to a portion of an immunoglobulin molecule that has a more conserved amino acid sequence than another portion of the immunoglobulin that contains the antigen binding site, the variable domain. The constant domain contains the C H 1. C H 2 and C H 3 domains (collectively referred to as C H ) and light chain C L Structural domain.

[0081] The light chains of antibodies (immunoglobulins) from any mammalian species are assigned to one of two different types (κ and λ) based on the amino acid sequences of their constant regions.

[0082] Human IgG Fc region C H The 1 domain, also referred to as "C1" of the "H1" domain, generally extends from about amino acid 118 to about amino acid 215 based on the EU numbering system.

[0083] The term "hinge region" refers to the region of IgG corresponding to Glu216 to Pro230 of human IgG1 based on the EU numbering system. Burton, Molec. Immunol., Vol. 22: pp. 161-206 (1985).

[0084] Human IgG Fc region C H The 2 domain, also referred to as "C2" of the "H2" domain, generally extends from about amino acid 231 to about amino acid 340 based on the EU numbering system.

[0085] Human IgG Fc region C H The 3 domain, also called the "C3" or "H3" domain, includes the residues between the C-terminus and the CH2 domain in the Fc region, i.e., from about amino acid 341 to the C-terminus of an antibody sequence based on the EU numbering system, typically at amino acid 446 or amino acid 447 of an IgG.

[0086] The term "Fc region" or "fragment crystallizable region" refers to the C-terminal region of an immunoglobulin heavy chain. The human IgG heavy chain Fc region generally extends from Cys226 or Pro230 based on the EU numbering system to the C-terminus. In certain embodiments, the C-terminal lysine of the Fc region is removed. Native sequence Fc regions suitable for use in antibodies or constructs described herein include the Fc regions of human IgG1, IgG2, IgG2A, IgG2B, IgG3, and IgG4.

[0087] The term "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. In certain embodiments, the FcR is a human FcR. In certain embodiments, the FcR is a native human FcR. In certain embodiments, the FcR is an FcR that binds to an IgG antibody (e.g., a gamma receptor). Ravetch and Kinet, Annu. Rev. Immunol., Vol. 9: 457-492 (1991); Capel et al., Immunomethods, Vol. 4: 25-34 (1994); de Haas et al., J. Lab. Clin. Med., Vol. 126: 330-341 (1995). In certain embodiments, the FcR is an FcγRI receptor, an FcγRIIA receptor ("activating receptor"), an FcγRIIB receptor ("inhibiting receptor"), an FcγRII receptor, or an FcγRIII receptor; or an allelic variant or alternatively spliced ​​form thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. Annu. Rev. Immunol., Vol. 15: 203-234 (1997).

[0088] As used herein, a first antibody or fragment thereof "competes" for binding to a target antigen with a second antibody or fragment thereof at an equimolar concentration to the first antibody or fragment thereof by at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, or vice versa. A high throughput method for "binning" antibodies based on cross-competition of antibodies is described in WO 03 / 48731.

[0089] As used herein, the term "cytokine" is understood to refer to any protein or peptide, analog or functional fragment thereof, which is capable of stimulating or inducing a cytocidal immune response against a preselected cell type (e.g., cancer cells or virus-infected cells) in a mammal. Therefore, it is contemplated that a variety of cytokines may be incorporated into the present disclosure. Useful cytokines include, for example, tumor necrosis factor (TNF), interleukin (IL), lymphokine (L), colony stimulating factor (CSF), interferon (IFN), including species variants and truncated analogs thereof that are capable of stimulating or inducing such a cytocidal immune response. Useful tumor necrosis factors include, for example, TNFα. Useful lymphokines include, for example, LT. Useful colony stimulating factors include, for example, GM-CSF and M-CSF. Useful interleukins include, for example, IL-2, IL-4, IL-5, IL-7, IL-12, IL-15, IL-18, IL-21, IL22, and IL-33. Useful interferons include, for example, IFN-α, IFN-β and IFN-γ. The term "cytokine" should also be understood to include any variant of a wild-type cytokine (such as IL-21, IL-7 and IL-15) that includes modifications and retains at least a significant portion (such as at least about 50%) of any desired function thereof.

[0090] The term "subject" refers to an animal, including but not limited to primates (e.g., humans), cattle, pigs, sheep, goats, horses, dogs, cats, rabbits, rats, or mice. The terms "subject," "individual," and "patient" are used interchangeably herein, e.g., to refer to a mammalian subject, such as a human. In one embodiment, the subject is a human.

[0091] The term "treat" is meant to include alleviating or eliminating a condition, disease or disorder, or one or more symptoms associated with the condition, disease or disorder; or alleviating or eradicating the cause of the condition, disease or disorder itself.

[0092] The term "preventing" refers to methods that include delaying and / or excluding the onset of a condition, disease or disorder and / or its attendant symptoms; preventing a subject from acquiring a condition, disease or disorder; or reducing a subject's risk of developing a condition, disease or disorder.

[0093] The term "alleviate" refers to relieving or reducing one or more symptoms (e.g., pain) of a condition, disease, or disorder. The term may also refer to reducing side effects associated with an active ingredient. Sometimes, the beneficial effects a subject receives from a preventive or therapeutic agent do not cure the condition, disease, or disorder.

[0094] The term "contacting" refers to bringing a therapeutic agent and a cell or tissue together so that a physiological and / or chemical effect occurs as a result of such contact. Contact can occur in vitro, ex vivo, or in vivo. In one embodiment, a therapeutic agent is contacted with cells in cell culture (in vitro) to determine the effect of the therapeutic agent on the cells. In another embodiment, contacting a therapeutic agent with a cell or tissue comprises administering a therapeutic agent to a subject having the cell or tissue to be contacted.

[0095] The term "therapeutically effective amount" or "effective amount" refers to an amount of the compound administered that is sufficient to prevent the development of one or more symptoms of the condition, disease or disorder being treated or to alleviate to some extent one or more symptoms of the condition, disease or disorder being treated. The term "therapeutically effective amount" or "effective amount" also refers to an amount of a compound that is sufficient to elicit the biological or medical response of a biomolecule (e.g., protein, enzyme, RNA or DNA), cell, tissue, system, animal or human being that is being sought by a researcher, veterinarian, medical doctor or clinician.

[0096] The term "IC 50 ” or “EC 50 ” refers to the amount, concentration or dose of a compound required to inhibit 50% of a maximal response in an assay measuring that response.

[0097] The terms "pharmaceutically acceptable carrier", "pharmaceutically acceptable excipient", "physiologically acceptable carrier" or "physiologically acceptable excipient" refer to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, solvent or encapsulating material. In one embodiment, each component is "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical formulation, and suitable for contact with the tissues or organs of a subject (e.g., a human or animal) without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications, and commensurate with a reasonable benefit / risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 22nd ed.; Allen, ed.; Pharmaceutical Press: London, 2012; Handbook of Pharmaceutical Excipients, 8th ed.; Sheskey et al., eds.; Pharmaceutical Press: London, 2017; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds.; Synapse Information Resources, 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson, ed.; Drugs and the Pharmaceutical Sciences 199; Informa Healthcare, New York, NY, 2009.

[0098] The term "about" or "approximately" refers to the acceptable error of a particular value determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" or "approximately" refers to within 1, 2, or 3 standard deviations. In certain embodiments, the term "about" or "approximately" refers to within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.

[0099] In the context of cancer, the term "treating" includes any or all of the following: inhibiting the growth of cancer cells, inhibiting the replication of cancer cells, reducing the overall tumor burden, and ameliorating one or more symptoms associated with the disease.

[0100] II. Anti-albumin constructs

[0101] In one embodiment, an anti-albumin construct is provided which comprises a single domain antibody (sdAb) portion that specifically binds to albumin.

[0102] In another embodiment, an isolated anti-albumin construct is provided, comprising a sdAb portion that specifically binds to albumin.

[0103] In certain embodiments, the anti-albumin constructs provided herein are present in an amount of about 10 -6 M to about 10 -10 M or about 10 -6 M to about 10 -8 K in the M range D Binds to albumin.

[0104] In certain embodiments, the anti-albumin constructs provided herein have a K in the range D Albumin binding: about 10 -5 M to about 10 -6 M, about 10 -6 M to about 10 -7 M, about 10 -7 M to about 10 -8 M, about 10 -8 M to about 10 -9 M, about 10 -9 M to about 10 -10 M, about 10 -10 M to about 10 -11 M, about 10 -11 M to about 10 -12 M, about 10 -6 M to about 10 -10 M, about 10 -6 M to about 10 -12 M, about 10 -6 M to about 10 -8 M, about 10 -8 M to about 10 -12 M, about 10 -9 M to about 10 -12 M, about 10 -10 M to about 10 -12 M, about 10 -5 M to about 10 - 11 M, about 10 -7 M to about 10 -11 M, about 10 -8 M to about 10 -11 M, about 10 -9 M to about 10 -11 M, about 10 -5 M to about 10 -10M, about 10 -7 M to about 10 -10 M, about 10 -8 M to about 10 -10 M, about 10 -5 M to about 10 -9 M, about 10 -7 M to about 10 -9 M, about 10 -5 M to about 10 -8 M or about 10 -6 M to about 10 -8 M.

[0105] In certain embodiments, the anti-albumin constructs provided herein are at a pH of about 7 at about 10 -6 M to about 10 -10 M or about 10 -6 M to about 10 -8 K in the M range D Binds to albumin.

[0106] In certain embodiments, the anti-albumin constructs provided herein have a pH of about 7 with a K in the range of D Albumin binding: about 10 -5 M to about 10 -6 M, about 10 -6 M to about 10 -7 M, about 10 -7 M to about 10 -8 M, about 10 -8 M to about 10 -9 M, about 10 -9 M to about 10 -10 M, about 10 -10 M to about 10 -11 M, about 10 -11 M to about 10 -12 M, about 10 -6 M to about 10 -10 M, about 10 -6 M to about 10 -12 M, about 10 -6 M to about 10 -8 M, about 10 -8 M to about 10 -12 M, about 10 -9 M to about 10 -12 M, about 10 -10 M to about 10 -12 M, about 10 - 5 M to about 10 -11 M, about 10 -7 M to about 10 -11M, about 10 -8 M to about 10 -11 M, about 10 -9 M to about 10 -11 M, about 10 -5 M to about 10 -10 M, about 10 -7 M to about 10 -10 M, about 10 -8 M to about 10 -10 M, about 10 -5 M to about 10 -9 M, about 10 -7 M to about 10 -9 M, about 10 -5 M to about 10 -8 M or about 10 -6 M to about 10 -8 M.

[0107] In certain embodiments, the anti-albumin constructs provided herein are at a pH of about 5.5 at about 10 -6 M to about 10 -10 M or about 10 -6 M to about 10 -8 K in the M range D Binds to albumin.

[0108] In certain embodiments, the anti-albumin constructs provided herein have a pH of about 5.5 with a K in the range of D Albumin binding: about 10 -5 M to about 10 -6 M, about 10 -6 M to about 10 -7 M, about 10 -7 M to about 10 -8 M, about 10 -8 M to about 10 -9 M, about 10 -9 M to about 10 -10 M, about 10 -10 M to about 10 -11 M, about 10 -11 M to about 10 -12 M, about 10 -6 M to about 10 -10 M, about 10 -6 M to about 10 -12 M, about 10 -6 M to about 10 -8 M, about 10 -8 M to about 10 -12 M, about 10 -9 M to about 10 -12 M, about 10-10 M to about 10 -12 M, about 10 - 5 M to about 10 -11 M, about 10 -7 M to about 10 -11 M, about 10 -8 M to about 10 -11 M, about 10 -9 M to about 10 -11 M, about 10 -5 M to about 10 -10 M, about 10 -7 M to about 10 -10 M, about 10 -8 M to about 10 -10 M, about 10 -5 M to about 10 -9 M, about 10 -7 M to about 10 -9 M, about 10 -5 M to about 10 -8 M or about 10 -6 M to about 10 -8 M.

[0109] The anti-albumin constructs provided herein bind to albumin with a K D It can be determined by methods known in the art, including but not limited to ELISA, radioligand binding assay (RIA), surface plasmon resonance (SPR) technology, affinity chromatography, fluorescence resonance energy transfer (FRET), and isothermal titration calorimetry (ITC).

[0110] In certain embodiments, the anti-albumin constructs provided herein bind to albumin at a K on Range: Approximately 10 2 M -1 s -1 to about 10 4 M -1 s -1 , about 10 4 M -1 s -1 to about 10 6 M -1 s -1 , about 10 6 M -1 s -1 to about 10 7 M -1 s -1 , about 10 2 M -1 s -1 to about 10 7 M-1 s -1 , about 10 3 M -1 s -1 to about 10 7 M -1 s -1 , about 10 4 M -1 s -1 to about 10 7 M -1 s -1 , about 10 5 M -1 s -1 to about 10 7 M -1 s -1 , about 10 3 M -1 s -1 to about 10 6 M -1 s -1 or about 10 4 M -1 s -1 to about 10 6 M -1 s -1 .

[0111] In certain embodiments, the anti-albumin constructs provided herein bind to albumin at a K off Range: about 1s -1 to about 10 -2 s -1 , about 10 -2 s -1 to about 10 -4 s -1 , about 10 -4 s -1 to about 10 -5 s -1 , about 10 -5 s -1 to about 10 -6 s -1 , about 1s -1 to about 10 -6 s -1 , about 10 -2 s -1 to about 10 -6 s -1 , about 10 -3 s -1 to about 10 -6 s -1 , about 10 -4 s -1 to about 10 -6s -1 , about 10 -2 s -1 to about 10 -5 s -1 or about 10 -3 s -1 to about 10 -5 s -1 .

[0112] In certain embodiments, the anti-albumin constructs provided herein bind to albumin with a K of about 7 at a pH of about 1. on Range: Approximately 10 2 M -1 s -1 to about 10 4 M -1 s -1 , about 10 4 M -1 s -1 to about 10 6 M -1 s -1 , about 10 6 M -1 s -1 to about 10 7 M -1 s -1 , about 10 2 M -1 s -1 to about 10 7 M -1 s -1 , about 10 3 M -1 s -1 to about 10 7 M -1 s -1 , about 10 4 M -1 s -1 to about 10 7 M -1 s -1 , about 10 5 M -1 s -1 to about 10 7 M -1 s -1 , about 10 3 M -1 s -1 to about 10 6 M -1 s -1 or about 10 4 M -1 s -1 to about 10 6 M-1 s -1 .

[0113] In certain embodiments, the anti-albumin constructs provided herein bind to albumin with a K of about 7 at a pH of about 1. off Range: about 1s -1 to about 10 -2 s -1 , about 10 -2 s -1 to about 10 -4 s -1 , about 10 -4 s -1 to about 10 -5 s -1 , about 10 -5 s -1 to about 10 -6 s -1 , about 1s -1 to about 10 -6 s -1 , about 10 -2 s -1 to about 10 -6 s -1 , about 10 -3 s -1 to about 10 -6 s -1 , about 10 -4 s -1 to about 10 -6 s -1 , about 10 -2 s -1 to about 10 -5 s -1 or about 10 -3 s -1 to about 10 -5 s -1 .

[0114] In certain embodiments, the anti-albumin constructs provided herein bind to albumin with a K of about 5.5 at a pH of about 5.5. on Range: Approximately 10 2 M -1 s -1 to about 10 4 M -1 s -1 , about 10 4 M -1 s -1 to about 10 6 M -1 s -1 , about 10 6 M -1 s -1to about 10 7 M -1 s -1 , about 10 2 M -1 s -1 to about 10 7 M -1 s -1 , about 10 3 M -1 s -1 to about 10 7 M -1 s -1 , about 10 4 M -1 s -1 to about 10 7 M -1 s -1 , about 10 5 M -1 s -1 to about 10 7 M -1 s -1 , about 10 3 M -1 s -1 to about 10 6 M -1 s -1 or about 10 4 M -1 s -1 to about 10 6 M -1 s -1 .

[0115] In certain embodiments, the anti-albumin constructs provided herein bind to albumin with a K of about 5.5 at a pH of about 5.5. off Range: about 1s -1 to about 10 -2 s -1 , about 10 -2 s -1 to about 10 -4 s -1 , about 10 -4 s -1 to about 10 -5 s -1 , about 10 -5 s -1 to about 10 -6 s -1 , about 1s -1 to about 10 -6 s -1 , about 10 -2 s -1 to about 10 -6 s-1 , about 10 -3 s -1 to about 10 -6 s -1 , about 10 -4 s -1 to about 10 -6 s -1 , about 10 -2 s -1 to about 10 -5 s -1 or about 10 -3 s -1 to about 10 -5 s -1 .

[0116] In yet another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that competes for binding to albumin with any of the anti-albumin sdAb constructs described herein. In certain embodiments, the competitive binding is determined using an ELISA assay.

[0117] In one embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin competitively with an anti-albumin sdAb construct, the anti-albumin sdAb portion comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150.

[0118] In another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin competitively with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53 and 105-115.

[0119] In yet another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin competitively with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising: a CDR1 comprising an amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135, or 138; a CDR2 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136, or 139. CDR3 of NO:12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140.

[0120] In yet another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin competitively with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53.

[0121] In another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin in competition with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising: a CDR1 comprising an amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31 or 34; a CDR2 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32 or 35; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 12, 15, 18, 21, 24, 27, 30, 33 or 36.

[0122] In yet another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin competitively with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising the amino acid sequence of any one of SEQ ID NOs: 105-115.

[0123] In another embodiment, an anti-albumin construct is provided, comprising an anti-albumin sdAb portion that specifically binds to albumin in competition with the anti-albumin sdAb construct, the anti-albumin sdAb portion comprising: a CDR1 comprising an amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising an amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140.

[0124] A. Anti-albumin single domain antibody portion

[0125] sdAbs differ from conventional 4-chain antibodies in that they have a single monomeric antibody variable domain, such as the heavy chain variable domain (V H H), which can show high affinity for antigen without the help of light chains. Camelidae V H H is the smallest functional antigen-binding fragment known with a molecular weight of approximately 15 kDa.

[0126] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising an amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135 or 138, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136 or 139, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136 or 139, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and A CDR3 of the amino acid sequence of NO:12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0127] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136 or 139. NO:12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140 amino acid sequence CDR3; or its variants comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitution is in CDR1 and / or CDR2.

[0128] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 13, 16, 19, 22, 25, 28, 31, 34, 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, 14, 17, 20, 23, 26, 29, 32, 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, 15, 18, 21, 24, 27, 30, 33, 36, 117, 120, 123, 126, 128, 131, 134, 137 or 140.

[0129] In another embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 31 and 34, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 11, 14, 17, 20, 23, 26, 29, 32 and 35, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 12, 15, 18, 21, 24, 27, 30, 33 and 36, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0130] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 31 and 34; a CDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 11, 14, 17, 20, 23, 26, 29, 32 and 35; and a CDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 12, 15, 18, 21, 24, 27, 30, 33 and 36; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0131] In another embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 31 and 34; a CDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 11, 14, 17, 20, 23, 26, 29, 32 and 35; and a CDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 12, 15, 18, 21, 24, 27, 30, 33 and 36.

[0132] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0133] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0134] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:10; a CDR2 comprising the amino acid sequence of SEQ ID NO:11; and a CDR3 comprising the amino acid sequence of SEQ ID NO:12.

[0135] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 13, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0136] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR2 comprising the amino acid sequence of SEQ ID NO: 14; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0137] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:13; a CDR2 comprising the amino acid sequence of SEQ ID NO:14; and a CDR3 comprising the amino acid sequence of SEQ ID NO:15.

[0138] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 16, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0139] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR2 comprising the amino acid sequence of SEQ ID NO: 17; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0140] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:16; a CDR2 comprising the amino acid sequence of SEQ ID NO:17; and a CDR3 comprising the amino acid sequence of SEQ ID NO:18.

[0141] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 19, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 20, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0142] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0143] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21.

[0144] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0145] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 22; a CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0146] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:22; a CDR2 comprising the amino acid sequence of SEQ ID NO:23; and a CDR3 comprising the amino acid sequence of SEQ ID NO:24.

[0147] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 25, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 26, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0148] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 25; a CDR2 comprising the amino acid sequence of SEQ ID NO: 26; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 27; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0149] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:25; a CDR2 comprising the amino acid sequence of SEQ ID NO:26; and a CDR3 comprising the amino acid sequence of SEQ ID NO:27.

[0150] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 28, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 29, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 30, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0151] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 28; a CDR2 comprising the amino acid sequence of SEQ ID NO: 29; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 30; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0152] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:28; a CDR2 comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 comprising the amino acid sequence of SEQ ID NO:30.

[0153] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO:31, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO:32, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO:33, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0154] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 31; a CDR2 comprising the amino acid sequence of SEQ ID NO: 32; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 33; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0155] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:31; a CDR2 comprising the amino acid sequence of SEQ ID NO:32; and a CDR3 comprising the amino acid sequence of SEQ ID NO:33.

[0156] In one embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 34, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 36, or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions.

[0157] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 34; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 36; or a variant thereof comprising up to about 3 (such as 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0158] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:34; a CDR2 comprising the amino acid sequence of SEQ ID NO:35; and a CDR3 comprising the amino acid sequence of SEQ ID NO:36.

[0159] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0160] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising an amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising an amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising an amino acid sequence of SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0161] In another embodiment, an anti-albumin sdAb portion is provided, which includes: a CDR1 comprising the amino acid sequence of SEQ ID NO: 116, 118, 121, 124, 129, 132, 135 or 138; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, 119, 122, 125, 127, 130, 133, 136 or 139; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117, 120, 123, 126, 128, 131, 134, 137 or 140.

[0162] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 116, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0163] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 116; a CDR2 comprising the amino acid sequence of SEQ ID NO: 35; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 117; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0164] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:116; a CDR2 comprising the amino acid sequence of SEQ ID NO:35; and a CDR3 comprising the amino acid sequence of SEQ ID NO:117.

[0165] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 118, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 119, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 120, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0166] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 118; a CDR2 comprising the amino acid sequence of SEQ ID NO: 119; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 120; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0167] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:118; a CDR2 comprising the amino acid sequence of SEQ ID NO:119; and a CDR3 comprising the amino acid sequence of SEQ ID NO:120.

[0168] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0169] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0170] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:121; a CDR2 comprising the amino acid sequence of SEQ ID NO:122; and a CDR3 comprising the amino acid sequence of SEQ ID NO:123.

[0171] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 124, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 125, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0172] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 124; a CDR2 comprising the amino acid sequence of SEQ ID NO: 125; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 126; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0173] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:124; a CDR2 comprising the amino acid sequence of SEQ ID NO:125; and a CDR3 comprising the amino acid sequence of SEQ ID NO:126.

[0174] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 127, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 128, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0175] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121; a CDR2 comprising the amino acid sequence of SEQ ID NO: 127; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 128; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0176] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:121; a CDR2 comprising the amino acid sequence of SEQ ID NO:127; and a CDR3 comprising the amino acid sequence of SEQ ID NO:128.

[0177] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122 or 127, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123 or 128, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0178] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122 or 127; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123 or 128; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0179] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 121; a CDR2 comprising the amino acid sequence of SEQ ID NO: 122 or 127; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 123 or 128.

[0180] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 129, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 130, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 131, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0181] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 129; a CDR2 comprising the amino acid sequence of SEQ ID NO: 130; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 131; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0182] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:129; a CDR2 comprising the amino acid sequence of SEQ ID NO:130; and a CDR3 comprising the amino acid sequence of SEQ ID NO:131.

[0183] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 132, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 133, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 134, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0184] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 132; a CDR2 comprising the amino acid sequence of SEQ ID NO: 133; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 134; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0185] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:132; a CDR2 comprising the amino acid sequence of SEQ ID NO:133; and a CDR3 comprising the amino acid sequence of SEQ ID NO:134.

[0186] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 135, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 136, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 137, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0187] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 135; a CDR2 comprising the amino acid sequence of SEQ ID NO: 136; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 137; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0188] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:135; a CDR2 comprising the amino acid sequence of SEQ ID NO:136; and a CDR3 comprising the amino acid sequence of SEQ ID NO:137.

[0189] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 138, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; a CDR2 comprising the amino acid sequence of SEQ ID NO: 139, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 140, or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions.

[0190] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 138; a CDR2 comprising the amino acid sequence of SEQ ID NO: 139; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 140; or a variant thereof comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the CDR region. In certain embodiments, the amino acid substitutions are in CDR1 and / or CDR2.

[0191] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO:138; a CDR2 comprising the amino acid sequence of SEQ ID NO:139; and a CDR3 comprising the amino acid sequence of SEQ ID NO:140.

[0192] In one embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150; H H domain, or a variant thereof having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150.

[0193] In another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150; H H domain, or its V HVariants comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the H domain.

[0194] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53 and 105-115; H H domain, or a variant thereof having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 1-9, 45-53 and 105-115.

[0195] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9, 45-53 and 105-115; H H domain, or its V H Variants comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the H domain.

[0196] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain, or a variant thereof having at least about 80% (such as at least any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity to any of SEQ ID NOs: 1-9 and 45-53.

[0197] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain, or its V H Variants comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the H domain.

[0198] In one embodiment, the anti-albumin sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain or variants thereof, the anti-albumin sdAb portion comprises amino acid substitutions in CDRs (such as CDR1, and / or CDR2, and / or CDR3 of any one of SEQ ID NOs: 1-9 and 45-53).

[0199] In another embodiment, the anti-albumin sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain or a variant thereof, the anti-albumin sdAb portion comprises CDR1, CDR2 and CDR3 of any one of SEQ ID NOs: 1-9 and 45-53, and comprises amino acid substitutions in FR (such as FR1, and / or FR2, and / or FR3, and / or FR4 of any one of SEQ ID NOs: 1-9 and 45-53).

[0200] In yet another embodiment, the anti-albumin sdAb portion comprises: a domain comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53, or a variant thereof, the anti-albumin sdAb portion comprising amino acid substitutions in both CDRs and FRs.

[0201] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 1-9 and 45-53; H H domain.

[0202] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising CDR1, CDR2 and CDR3 of any one of SEQ ID NOs: 1-9 and 45-53.

[0203] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain, or a variant thereof having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 105-115.

[0204] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain, or its V H Variants comprising up to about 3 (in one embodiment, 1, 2 or 3) amino acid substitutions in the H domain.

[0205] In one embodiment, the anti-albumin sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; HH domain or variants thereof, the anti-albumin sdAb portion comprises amino acid substitutions in CDRs (such as CDR1, and / or CDR2, and / or CDR3 of any one of SEQ ID NOs: 105-115).

[0206] In another embodiment, the anti-albumin sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain or a variant thereof, the anti-albumin sdAb portion comprises CDR1, CDR2 and CDR3 of any one of SEQ ID NOs: 105-115, and comprises amino acid substitutions in FR (such as FR1, and / or FR2, and / or FR3, and / or FR4 of any one of SEQ ID NOs: 105-115).

[0207] In yet another embodiment, the anti-albumin sdAb portion comprises: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain or a variant thereof, the anti-albumin sdAb portion comprises amino acid substitutions in both CDRs and FRs.

[0208] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising: a V comprising the amino acid sequence of any one of SEQ ID NOs: 105-115; H H domain.

[0209] In yet another embodiment, an anti-albumin sdAb portion is provided, comprising CDR1, CDR2 and CDR3 of any one of SEQ ID NOs: 105-115.

[0210] In certain embodiments, the anti-albumin sdAb portion is camelid, chimeric, human, partially humanized, or fully humanized.

[0211] Single domain antibodies

[0212] In one embodiment, the anti-albumin construct described herein is an anti-albumin sdAb.

[0213] Exemplary sdAbs include, but are not limited to, heavy chain variable domains from heavy chain antibodies (e.g., V H H (heavy chain variable domain of heavy chain antibodies) or V in cartilaginous fish NAR (variable domain of shark neoantigen receptor)), single domains (such as V H or V L).

[0214] In certain embodiments, the sdAbs described herein are derived from mouse, rat, human, camel, llama, lamprey, fish, shark, goat, rabbit, or cow.

[0215] In certain embodiments, the sdAbs described herein are derived from naturally occurring single-domain antigen-binding molecules, referred to as heavy chain antibodies lacking light chains, also referred to as heavy chain antibodies or "HCAbs". See, e.g., WO 94 / 04678 and Hamers-Casterman et al., Nature, Vol. 363: pp. 446-448 (1993). For clarity, the variable domains derived from naturally occurring heavy chain molecules lacking light chains are referred to herein as V H H, to compare it with the conventional V H In certain embodiments, V H H is derived from an antibody produced in a species of the Camelidae family, such as a camel, llama, llama, dromedary, alpaca or guanaco.

[0216] In certain embodiments, the sdAb described herein is derived from the variable region of an immunoglobulin present in cartilaginous fish. In certain embodiments, the sdAb described herein is derived from an immunoglobulin isotype called a novel antigen receptor (NAR) present in shark serum. Methods for producing single domain antibodies derived from NAR ("IgNAR") variable regions are described in WO 03 / 014161 and Streltsov, Protein Sci., Vol. 14: pp. 2901-2909 (2005).

[0217] In certain embodiments, the sdAbs described herein are recombinant, CDR-grafted, humanized, camelized, deimmunized, or produced in vitro (e.g., selected by phage display). In certain embodiments, the amino acid sequence of the sdAb framework region is altered by "camelization" of specific amino acid residues in the framework region. Camelization refers to the use of amino acids present in the heavy chain antibody V H One or more amino acid residues at corresponding positions in the H domain are substituted or replaced with the (naturally occurring) V domain from a conventional four-chain antibody. H Preferably, such "camelizing" substitutions are inserted into one or more amino acid residues forming and / or present in a V H -V LThe amino acid positions of the interfaces and / or so-called Camelidae Hallmark Residues as defined herein. See, for example, WO 94 / 04678, Davies and Riechmann, FEBS Lett., Vol. 339: pp. 285-290 (1994); Davies and Riechmann, Protein Engin., Vol. 9: pp. 531-537 (1996); Riechmann, J. Mol. Biol., Vol. 259: pp. 957-969 (1996); Riechmann and Muyldermans, J. Immunol. Methods, Vol. 231: pp. 25-38 (1999).

[0218] In certain embodiments, the sdAb described herein is a human sdAb produced by a transgenic mouse or rat expressing a human heavy chain segment. See, for example, US 2009 / 0307787A1, US 2015 / 0289489A1, US 2010 / 0122358A1, US8,754,287, and WO 2004 / 049794. In certain embodiments, the sdAb described herein has a mature affinity.

[0219] In certain embodiments, the antibodies described herein contain naturally occurring V sequences directed against a particular antigen or target. H The H domain of sdAb was obtained from camel V H H sequences from a primary or immune library. See, for example, WO 99 / 37681, WO 01 / 90190, WO03 / 025020, and WO 03 / 035694. In certain embodiments, a primary or immune V H Improved synthetic or semisynthetic libraries of V H libraries, for example, from primary or immune V H libraries by techniques such as random mutagenesis and / or CDR shuffling. H V obtained from H library H H library. See, e.g., WO 00 / 43507.

[0220] In certain embodiments, the sdAb described herein is generated by a conventional 4-chain antibody. See, e.g., EP 0 368684; WO 06 / 030220; WO 06 / 003388; Ward et al., Nature, Vol. 341: 544-546 (1989); Holt et al., Trends Biotechnol., Vol. 21: 484-490 (2003).

[0221] Due to the unique properties of sdAb, compared with conventional V H and V L, scFv and conventional antibody fragments (such as Fab or (Fab')2), using V H The H domain as a single antigen-binding protein or domain (i.e., as part of a larger protein, polypeptide or construct) offers a number of further significant advantages: 1) only a single domain is required to bind to the antigen with high affinity, without the need for a second domain and without the need to ensure that the two domains are in the correct spatial conformation and configuration (e.g., no need to pair the heavy and light chains during folding, nor the need to use specially designed linkers, such as those used for scFvs); 2) V H The H domain or sdAb can be expressed from a single gene without the need for post-translational folding or modification; 3) V H H domains or sdAbs can be easily engineered into multivalent and / or multispecific formats (such as the anti-albumin constructs described herein); 4) V H The H domain or sdAb is highly soluble, thus reducing its tendency to aggregate (compared to, for example, the mouse-derived "dAb" described in Ward et al., Nature, Vol. 341: 544-546 (1989)); 5) V H The H domain or sdAb is highly stable to heat, pH or proteases; 6) V H H domains or sdAbs are easy and relatively cheap to produce even on a large scale (such as using microbial fermentation) without the need for mammalian expression systems (as required for the production of, for example, conventional antibody fragments); 7) Compared with conventional 4-chain antibodies and their antigen-binding fragments, V H The H domain or sdAb is relatively small (approximately 15 kDa or 10 times smaller than conventional IgG) and therefore has high (higher) tissue penetration ability, for example, for solid tumors and dense tissues; 8) V H H domains or sdAbs can exhibit so-called “cavity binding properties” (due to the presence of H The CDR3 loop is longer than its structural domain) and can therefore access targets or epitopes that are inaccessible to conventional 4-chain antibodies or antigen-binding fragments thereof. For example, it has been shown that V H The H domain or sdAb can inhibit the enzyme. See, for example, WO 1997 / 049805; Transue et al., Proteins, Vol. 32: 515-522 (1998); Lauwereys et al., EMBO J., Vol. 17: 3512-3520 (1998).

[0222] albumin

[0223] Albumin (e.g., human serum albumin or HSA) has been used to increase the serum half-life of biological drugs. See, for example, Dennis et al., J. Biol. Chem., Vol. 277: pp. 35035-35043 (2002); Adams et al., MABS, Vol. 8: pp. 1336-1346 (2016). For example, HSA has been used. HSA is the most abundant protein in the blood, widely distributed in tissues, and has non-acute functions. The half-life of HSA is 19 days. Therefore, in one embodiment, the albumin used herein (e.g., HSA) is used to increase the half-life of a drug (such as an anti-albumin construct described herein).

[0224] In certain embodiments, the albumin is selected from HSA, rhesus serum albumin (RhsA), cynomolgus serum albumin (CySA), and murine serum albumin (MuSA). In certain embodiments, the albumin is HSA.

[0225] Some isoforms of HSA are listed in Table 2 below. See, UniProtKB-P02768 (ALBU_HUMAN). In certain embodiments, the anti-albumin constructs provided herein bind to SEQ ID NO: 54, 55, 56 or 57.

[0226] Table 2. Isoforms of human serine albumin

[0227]

[0228]

[0229]

[0230] In certain embodiments, HSA is at least 90% identical to the amino acid sequence of SEQ ID NO: 54, 55, 56 or 57. In certain embodiments, HSA is at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% identical to the amino acid sequence of SEQ ID NO: 54, 55, 56 or 57. In certain embodiments, HSA has no more than 10 amino acid differences compared to SEQ ID NO: 54, 55, 56 or 57. In certain embodiments, HSA has no more than 5, 4, 3, 2 or 1 amino acid differences compared to SEQ ID NO: 54, 55, 56 or 57. In certain embodiments, HSA differs from SEQ ID NO: 54, 55, 56 or 57, for example, by having conservative mutations or mutations in non-conserved regions, and has substantially the same biological function as HSA of SEQ ID NO: 54, 55, 56 or 57.

[0231] In certain embodiments, the anti-albumin constructs described herein bind to any of the above-mentioned albumins. In certain embodiments, the anti-albumin constructs bind to the albumin of SEQ ID NO: 54, 55, 56 or 57.

[0232] Chimeric or humanized antibodies

[0233] In certain embodiments, the anti-albumin sdAb portion described herein is a chimeric antibody. Certain chimeric antibodies are described, for example, in US 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, Vol. 81: pp. 6851-6855 (1984). In one embodiment, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a camelid species such as a llama) and a human constant region. In another embodiment, a chimeric antibody is a "class-switched" antibody, in which the class or subclass has been changed from that of its parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0234] In certain embodiments, chimeric antibodies are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to people while retaining the specificity and affinity of the parent non-human antibody. Typically, humanized antibodies include one or more variable domains, wherein HVR, such as CDR (or a portion thereof) are derived from non-human antibodies, and FR (or a portion thereof) are derived from human antibody sequences. Humanized antibodies also optionally include at least a portion of a human constant region. In certain embodiments, some FR residues in humanized antibodies are replaced by corresponding residues from non-human antibodies (e.g., antibodies from which HVR residues are derived), for example, to restore or improve antibody specificity or affinity.

[0235] For a review of humanized antibodies and methods for their preparation, see, for example, Almagro and Fransson, Front. Biosci., Vol. 13: pp. 1619-1633 (2008). Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best fit" method; framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions; human mature (somatic mutation) framework regions or human germline framework regions; and framework regions derived from screening FR libraries.

[0236] In certain embodiments, anti-albumin sdAbs, such as humanized anti-albumin sdAbs, are modified without reducing the natural affinity of the domains for the antigen while reducing the immunogenicity of the anti-albumin sdAbs to heterologous species. For example, the antibody variable domains (V HH), and one or more camelid amino acids in the framework regions are replaced by their human counterparts present in the human consensus sequence, without the polypeptide losing its typical characteristics, i.e. the humanization does not significantly affect the antigen binding ability of the resulting polypeptide. Humanization of camelid single domain antibodies requires the introduction and mutagenesis of a limited number of amino acids in a single polypeptide chain. This is in contrast to the humanization of scFv, Fab', (Fab')2 and IgG, which requires the introduction of amino acid changes in two chains (light and heavy) and the maintenance of the assembly of these two chains.

[0237] Contains V H The sdAb of the H domain can be humanized to have a human-like sequence. In certain embodiments, the V H The FR region of the H domain comprises at least about 50%, 60%, 70%, 80%, 90%, 95% or more homology to any of the amino acid sequence homology of the human VH framework region. H The H domain is characterized by the following Kabat numbering: H H carries an amino acid selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, methionine, serine, threonine, asparagine or glutamine at position 45 (e.g. L45) and a tryptophan at position 103. Thus, polypeptides belonging to this class show high amino acid sequence homology to human VH framework regions and can be directly administered to humans without expecting an unnecessary immune response thereby and without the burden of further humanization.

[0238] Another exemplary class of humanized camelid single domain antibodies is described in WO 03 / 035694, which contain the hydrophobic FR2 residues normally present in conventional antibodies of human origin or from other species, but in which the charged arginine residue at position 103 is substituted for the diabody V1. H The conserved tryptophan residues present in V compensate for the loss of hydrophilicity. H The framework regions have high amino acid sequence homology, and the peptides can be directly administered to humans without expecting unnecessary immune responses thereby generated and without the burden of further humanization.

[0239] Human domain antibodies

[0240] In certain embodiments, the anti-albumin sdAb portion provided herein is a human antibody (referred to as a human domain antibody or human DAb). Human antibodies can be produced using various techniques known in the art. See, for example, Chen, Mol. Immunol., Vol. 47: pp. 912-21 (2010). Transgenic mice or rats capable of producing fully human single domain antibodies (or DAbs) are known in the art. See, for example, US 2009 / 0307787A1, US 8,754,287, US 2015 / 0289489A1, US2010 / 0122358A1, and WO 2004 / 049794.

[0241] Human antibodies (e.g., human DAbs) can be prepared by administering immunogens to transgenic animals that have been modified to produce complete human antibodies or complete antibodies with human variable regions in response to antigenic attack. Such animals typically contain all or part of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or they are present outside the chromosomes or randomly integrated into the chromosomes of the animals. In such transgenic mice, the endogenous immunoglobulin loci are typically inactivated. Methods for obtaining human antibodies from transgenic animals are reviewed in Lonberg, Nat. Biotech., Vol. 23: pp. 1117-1125 (2005). The human variable regions of the complete antibodies produced by such animals can be further modified, for example, by combining with different human constant regions.

[0242] Human antibodies (eg, human DAbs) can also be prepared by hybridoma-based methods. Human myeloma and mouse-human hybrid myeloma cell lines for the production of human monoclonal antibodies are known in the art.

[0243] Human antibodies (e.g., human DAbs) can also be produced by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences can then be combined with desired human constant domains. The technology for selecting human antibodies from antibody libraries is described below.

[0244] A method for obtaining V against a specific antigen or target H The technology of producing a heavy chain antibody involves appropriately immunizing a transgenic mammal capable of expressing a heavy chain antibody (i.e., so as to elicit an immune response and / or heavy chain antibody against the antigen or target), and obtaining a heavy chain antibody containing (a nucleic acid sequence encoding) the V H A suitable biological sample (such as a blood sample, a serum sample or a B cell sample) is obtained from the transgenic mammal containing the H sequence, and V against the antigen or target is then produced starting from the sample using any suitable technique known per se (such as any of the methods described herein or hybridoma technology). HH sequence. For example, for this purpose, mice expressing heavy chain antibodies and further methods and techniques described in WO 02 / 085945, WO 04 / 049794, WO 06 / 008548 and Janssens et al., Proc. Natl. Acad. Sci. USA, Vol. 103: pp. 15130-15135 (2006) can be used. For example, such mice expressing heavy chain antibodies can express heavy chain antibodies with any suitable (single) variable domain, such as (single) variable domains from natural sources (e.g., human (single) variable domains, camelid (single) variable domains or shark (single) variable domains), as well as, for example, synthetic or semisynthetic (single) variable domains.

[0245] Antibodies from libraries

[0246] The antibodies of the present disclosure can be isolated by screening combinatorial libraries for antibodies with the desired activity. For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies with the desired binding characteristics. Methods for constructing single domain antibody libraries have been described, for example, in US 7,371,849.

[0247] In some phage display methods, V H and V L Gene library, and random recombination in a phage library, which can then be screened for antigen binding phage, as described in Winter et al., Ann. Rev. Immunol., Vol. 12: pp. 433-455 (1994). Similarly, V can be cloned by PCR H H gene library, randomly recombined in a phage library, and screened for antigen-binding phage. Phages usually display antibody fragments (scFv fragments or Fab fragments). The library of immune origin provides high-affinity antibodies against immunogens without the need to construct hybridomas. Alternatively, as described in Griffiths et al., EMBO J., Vol. 12: pp. 725-734, 1993, the original library can be cloned (for example, from humans) to provide antibodies against a wide range of non-self antigens and self-antigens from a single source without any immunization. Finally, the original library can also be prepared by cloning unrearranged V gene fragments from stem cells and using PCR primers containing random sequences for encoding highly variable CDR3 regions and completing rearrangement in vitro, as described in Hoogenboom and Winter, J. Mol. Biol., Vol. 227: pp. 381-388 (1992).

[0248] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

[0249] Biological Activity

[0250] 1. Serum half-life

[0251] In certain embodiments, the biological activity of the anti-albumin sdAb moiety described herein is determined by its ability to extend the serum half-life of the anti-albumin construct comprising the anti-albumin sdAb moiety. In certain embodiments, when applied to an individual, the half-life of the anti-albumin construct is at least about 15 days, about 14 days, about 13 days, about 12 days, about 11 days, about 10 days, about 9 days, about 8 days, about 7 days, about 6 days, about 5 days, about 4 days, about 3 days, about 2 days, about 24 hours, about 22 hours, about 20 hours, about 18 hours, about 16 hours, about 14 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 3 hours, about 2 hours or about 1 hour. The anti-albumin construct can be administered by various routes, for example, intravenously, orally, subcutaneously or intraperitoneally.

[0252] In certain embodiments, the serum half-life of the anti-albumin construct is longer than that of the reference construct (such as at least about 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% longer). In certain embodiments, the serum half-life of the anti-albumin construct is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45 or 50 times longer than that of the reference construct. In certain embodiments, the reference construct does not have an anti-albumin sdAb portion, but comprises other functional portions identical to the anti-albumin construct.

[0253] 2. Stability

[0254] In certain embodiments, the biological activity of the anti-albumin sdAb portion described herein can be determined by its ability to improve the stability of the anti-albumin construct comprising the anti-albumin sdAb portion. In certain embodiments, the anti-albumin construct has a higher stability than the reference construct. In certain embodiments, the reference construct does not have an anti-albumin sdAb portion, but comprises other functional portions that are the same as the anti-albumin construct.

[0255] In certain embodiments, the stability comprises thermal stability.

[0256] In certain embodiments, the stability is assessed by the extent to which the anti-albumin construct retains an acceptable degree of chemical structure or biological function after storage under defined conditions. In certain embodiments, the anti-albumin construct has high stability even if it does not maintain 100% of its chemical structure or biological function after storage for a defined amount of time. In certain embodiments, maintaining about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the structure or function of an anti-albumin construct as described herein after storage for a defined amount of time can be considered to have high stability.

[0257] Stability can be measured, in particular, by determining the percentage of native (non-aggregating or non-degrading) anti-albumin constructs retained in a formulation (liquid or reconstituted) after a defined amount of storage at a defined temperature. The percentage of native anti-albumin constructs can be determined, in particular, by size exclusion chromatography (e.g., size exclusion high performance liquid chromatography (SE-HPLC)), whereby native means non-aggregating and non-degrading. In certain embodiments, at least about 90% (such as, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) of the native form of the anti-albumin construct can be detected in the formulation after a defined amount of storage at a given temperature. In certain embodiments, at least about 90% (such as at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) of the native form of the anti-albumin construct is detectable in the formulation after at least about 6 hours, at least about 8 hours, at least about 10 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 26 hours, at least about 28 hours, at least about 30 hours, at least about 32 hours, at least about 34 hours, at least about 36 hours, at least about 38 hours, at least about 40 hours, at least about 42 hours, at least about 44 hours, at least about 46 hours, or at least about 48 hours at room temperature (about 25°C).

[0258] Stability can be determined in particular by determining the percentage of anti-albumin constructs formed in the form of aggregates in a formulation (liquid or reconstituted) after storage for a defined amount of time at a defined temperature, wherein stability is inversely proportional to the percentage of aggregates formed. The percentage of aggregated anti-albumin constructs can be determined in particular by size exclusion chromatography (e.g., size exclusion high performance liquid chromatography (SE-HPLC)). In certain embodiments, less than about 10% (preferably less than about 5%) of the anti-albumin constructs are present as aggregates in the formulation after storage for a defined amount of time at a given temperature. In certain embodiments, the anti-albumin constructs described herein are substantially free of aggregation, e.g., no more than about 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1% of the anti-albumin constructs are detected in the formulation in the form of aggregates after storage at a given temperature for a defined amount of time, e.g., at least about 6 hours, at least about 8 hours, at least about 10 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 26 hours, at least about 28 hours, at least about 30 hours, at least about 32 hours, at least about 34 hours, at least about 36 hours, at least about 38 hours, at least about 40 hours, at least about 42 hours, at least about 44 hours, at least about 46 hours, or at least about 48 hours at room temperature (about 25°C).

[0259] Measuring the binding affinity of an anti-albumin construct to its target can also be used to assess stability. For example, if after storage for a defined amount of time (e.g., 6 hours, 12 hours, 24 hours, 36 hours, or 48 hours) at, for example, room temperature (about 25° C.), the antigen binding domain has an affinity that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or even higher than the binding affinity of the antibody before said storage, then the anti-albumin construct of the present disclosure can be considered stable. Binding affinity can be determined by any method, such as ELISA or plasma resonance. The binding of an anti-albumin construct to such cells can be measured directly, such as by FACS analysis.

[0260] 3. Clinical characteristics

[0261] In certain embodiments, the biological activity of the anti-albumin sdAb portion described herein is determined by its ability to improve the clinical properties of the anti-albumin construct comprising the anti-albumin sdAb portion. In certain embodiments, relative to the reference construct, the anti-albumin construct described herein has improved clinical properties. In certain embodiments, the reference construct does not have the anti-albumin sdAb portion, but comprises other functional portions identical to the anti-albumin construct. In certain embodiments, compared with the reference construct, the anti-albumin construct exhibits improved cytotoxic activity. In certain embodiments, compared with the reference construct, the anti-albumin construct exhibits higher anti-tumor effects (such as reducing tumor load and / or improving survival).

[0262] a) Cytotoxicity

[0263] The anti-albumin constructs described herein can be tested for cytotoxicity (such as ADCC activity) to cells using a number of assays. For example, cancer cell lines expressing antigens that can be recognized by the anti-albumin constructs and effector cells (e.g., PBMC cells) are mixed together in a 96-well plate. Different concentrations of the anti-albumin constructs are added. After incubation, EC 50 (represents ADCC activity).

[0264] In certain embodiments, the anti-albumin construct exhibits improved ADCC activity against cells compared to a reference construct. In certain embodiments, the EC of the cell-specific anti-albumin construct 50 No more than about 50%, 40%, 30%, 20%, 10% or less of a reference construct. In certain embodiments, the cell is a tumor cell.

[0265] b) Cancer treatment

[0266] In certain embodiments, the anti-albumin construct treats cancer in an individual (e.g., by inhibiting tumor growth). In certain embodiments, the anti-albumin construct exhibits an enhanced anti-cancer effect compared to a reference construct. For example, in certain embodiments, administration of the anti-albumin construct reduces tumor burden (such as a reduction in tumor volume of at least about 10%, 20%, 30%, 40%, or 50%) compared to a reference construct. In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a liquid tumor.

[0267] B. Constructs each comprising an anti-albumin sdAb portion

[0268] In certain embodiments, the anti-albumin construct comprises a first polypeptide and a second polypeptide, the first polypeptide comprising an anti-albumin sdAb portion.

[0269] Anti-albumin fusion protein

[0270] In certain embodiments, the anti-albumin construct comprises a second polypeptide fused to a first polypeptide comprising an anti-albumin sdAb portion.

[0271] In certain embodiments, the second polypeptide comprises an antigen binding portion. In certain embodiments, the antigen binding portion binds to a tumor antigen. In certain embodiments, the tumor is a solid tumor. In certain embodiments, the tumor is a liquid tumor. In certain embodiments, the tumor is a cancer selected from mesothelioma, lung cancer, breast cancer, ovarian cancer, pancreatic cancer, lymphoma, leukemia, head and neck cancer, liver cancer, esophageal cancer, gastric cancer and colorectal cancer. In certain embodiments, the cancer expresses a high level of tumor antigen. For example, in certain embodiments, the level of expression of the cancer is at least 2 times, 5 times, 10 times, 20 times, 30 times, 40 times or 50 times that of a reference tissue. In certain embodiments, the reference tissue is a tissue that does not contain cancer cells in the same individual.

[0272] In certain embodiments, the tumor antigen is selected from mesothelin (MSLN), GPA33, Her-2, EGFR and CD20. In certain embodiments, the tumor antigen is selected from CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA and BCMA.

[0273] In certain embodiments, the tumor antigen is mesothelin. In certain embodiments, the antigen binding portion comprises a single chain antibody comprising a heavy chain variable region (anti-MSLN V H ), wherein the anti-MSLN V H Comprising CDR1, CDR2 and CDR3, wherein: a) CDR1 comprising the amino acid sequence of SEQ ID NO: 92, CDR2 comprising the amino acid sequence of SEQ ID NO: 93, and CDR3 comprising the amino acid sequence of SEQ ID NO: NO: 94, or variants thereof comprising a total of up to 3, 2 or 1 amino acid substitutions in the CDRs; or b) CDR1 comprising the amino acid sequence of SEQ ID NO: 95, CDR2 comprising the amino acid sequence of SEQ ID NO: 96, and CDR3 comprising the amino acid sequence of GRY, or variants thereof comprising a total of up to 3, 2 or 1 amino acid substitutions in the CDRs.

[0274] In certain embodiments, the antigen is an immune checkpoint protein. In certain embodiments, the immune checkpoint protein is selected from PD-L1, CTLA4, PD-L2, PD-1, CD47, TIGIT, GITR, TIM3, LAG3, CD27, 4-1BB and B7H4.

[0275] In certain embodiments, the antigen binding portion is an antibody or an antigen binding fragment thereof. In certain embodiments, the antibody or its antigen binding fragment provided herein can be immunospecifically bound to an epitope of a polypeptide, polypeptide fragment or antigen expressed on a cancer cell. In one embodiment, the antibody binds to a human cancer antigen. In certain embodiments, the antibody or its antigen binding fragment provided herein binds to an extracellular domain (ECD) of a cancer antigen. In certain embodiments, the antibody binds to an epitope in the ECD of a cancer antigen. In certain embodiments, the cancer antigen is expressed on solid tumor cancer cells.

[0276] The antibodies that bind to the cancer antigens provided herein can be, but are not limited to, synthetic antibodies, monoclonal antibodies, recombinantly produced antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, intracellular antibodies, single-chain Fvs (scFv) (e.g., including monospecific and bispecific), camelized antibodies or humanized variants thereof, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments thereof.

[0277] In certain embodiments, antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules containing antigen binding sites that are immunospecifically bound to cancer antigens (e.g., solid tumor cancer antigens). Immunoglobulin molecules provided herein can be any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), category (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2) or subclass of immunoglobulin molecules. In a specific embodiment, antibodies provided herein are IgG antibodies, such as IgG1 antibodies.

[0278] The present disclosure also includes variants and derivatives of antibodies, including antibody fragments that retain the ability to specifically bind to cancer antigen epitopes. Exemplary fragments include Fab fragments; Fab'; F(ab')2; bispecific Fab; single-chain Fab chains (also referred to as sFv) comprising variable regions; Fv or dsFv connected by disulfide bonds; camelized VH; bispecific sFv; double antibodies; and three antibodies. Derivatives of antibodies also include one or more CDR sequences of the antibody binding site. When there are two or more CDR sequences, the CDR sequences can be connected together on the scaffold. In certain embodiments, the antibodies provided herein include single-chain Fv ("scFv"). Various techniques for producing antibody fragments have been developed, as briefly described in the above section.

[0279] In certain embodiments, the antigen binding moiety is a single variable domain antibody (sdAb) (such as a VH H antibody). Certain types of organisms (camelids and cartilaginous fish) have a single high-affinity V-like domain installed on an Fc equivalent domain structure as part of their immune system. Woolven et al., Immunogenetics, Vol. 50: 98-101 (1999); Streltsov et al., Proc. Natl. Acad. Sci. USA, Vol. 101: 12444-12449 (2004). The V-like domain (called V in camelids) H VH, called V-NAR in sharks, typically display long surface loops that allow penetration into the cavity of the target antigen. They also stabilize the isolated VH domain by masking a hydrophobic surface patch.

[0280] In certain embodiments, the second polypeptide comprises a cytokine, a growth factor, or a protein hormone.

[0281] In certain embodiments, the second polypeptide comprises a cytokine. In certain embodiments, the cytokine is selected from IL-21, IL-7, IL-15, IL-15, IL-33 and IL-22 bound to IL-15Rα or its fragment. In certain embodiments, the second polypeptide comprises IL-21. In certain embodiments, the IL-21 is human IL-21. In certain embodiments, the IL-21 comprises the amino acid sequence of SEQ ID NO:97 or 98, or a variant thereof having at least 80% (such as at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity to SEQ ID NO:97 or 98. In certain embodiments, the IL-21 is a variant lacking about 1 to about 10 amino acids between S124 and S133 in the amino acid sequence of SEQ ID NO:97.

[0282] In certain embodiments, IL-21 is a mutant protein comprising a substitution of one of the twenty natural amino acids other than R, R, K and R at the R5, R9, K73 or R76 position in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of one of the twenty natural amino acids other than R at the R5 position in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of one of the twenty natural amino acids other than R at the R9 position in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of one of the twenty natural amino acids other than K at the K73 position in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of one of the twenty natural amino acids other than R at the R76 position in the amino acid sequence of SEQ ID NO: 97.

[0283] In certain embodiments, IL-21 is a mutant protein comprising two, three or four substitutions of R5, R9, K73 and / or R76 positions in the amino acid sequence of SEQ ID NO: 97, each independently with one of the twenty natural amino acids other than R, R, K and R, respectively. In certain embodiments, IL-21 is a mutant protein comprising substitutions of R5 position and R9 position in the amino acid sequence of SEQ ID NO: 97, each independently with one of the twenty natural amino acids other than R. In certain embodiments, IL-21 is a mutant protein comprising substitutions of R5 position and K73 position in the amino acid sequence of SEQ ID NO: 97, each independently with one of the twenty natural amino acids other than R and K, respectively. In certain embodiments, IL-21 is a mutant protein comprising substitutions of R5 position and R76 position in the amino acid sequence of SEQ ID NO: 97, each independently with one of the twenty natural amino acids other than R. In certain embodiments, IL-21 is a mutant protein comprising a substitution of the R9 position and the K73 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R and K, respectively. In certain embodiments, IL-21 is a mutant protein comprising a substitution of the R9 position and the R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R, respectively. In certain embodiments, IL-21 is a mutant protein comprising a substitution of the K73 position and the R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than K and R, respectively. In certain embodiments, IL-21 is a mutant protein comprising a substitution of the R5 position, the R9 position, and the K73 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R, R, and K, respectively. In certain embodiments, IL-21 is a mutant protein comprising substitutions of the R5 position, the R9 position, and the R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R. In certain embodiments, IL-21 is a mutant protein comprising substitutions of the R5 position, the K73 position, and the R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R, K, and R, respectively.In certain embodiments, IL-21 is a mutant protein comprising substitutions of the R9 position, K73 position, and R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R, K, and R, respectively. In certain embodiments, IL-21 is a mutant protein comprising substitutions of the R5 position, R9 position, K73 position, and R76 position in the amino acid sequence of SEQ ID NO: 97 with one of the twenty natural amino acids other than R, R, K, and R, respectively, respectively.

[0284] In certain embodiments, IL-21 is a mutant protein comprising a substitution of R5A, R5E, R5N, R9A, R9E, R9N, K73A, K73E, K73N, R76A, R76E or R76N in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R5A, R5E or R5N in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R9A, R9E or R9N in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of K73A, K73E or K73N in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R76A, R76E or R76N in the amino acid sequence of SEQ ID NO: 97.

[0285] In certain embodiments, IL-21 is a mutant protein comprising a substitution of R5A, R5E, R9A, R9E, K73A, K73E, R76A or R76E in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R5A or R5E in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R9A or R9E in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of K73A or K73E in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising a substitution of R76A or R76E in the amino acid sequence of SEQ ID NO: 97.

[0286] In certain embodiments, IL-21 is a mutant protein comprising (i) R5N and (ii) M7S or M7T in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising (i) R9N and (ii) R11S or R11T in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising (i) K73N and (ii) K75S or K75T in the amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 is a mutant protein comprising (i) K76N and (ii) K78S or K78T in the amino acid sequence of SEQ ID NO: 97.

[0287] In certain embodiments, IL-21 has an amino acid sequence of any one of SEQ ID NOs: 97, 98, and 151 to 167. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 97. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 98. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 151. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 152. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 153. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 154. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 155. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 156. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 157. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 158. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 159. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 160. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 161. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 162. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 163. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 164. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 165. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 166. In certain embodiments, IL-21 has an amino acid sequence of SEQ ID NO: 167.

[0288] Other IL-21 sequences include those described in US 2019 / 0046611 A1, the disclosure of which is incorporated herein by reference in its entirety.

[0289] In one embodiment, IL-21 is glycosylated. In another embodiment, IL-21 is N-glycosylated.

[0290] In certain embodiments, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NXT or NXS, wherein each X is independently A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In certain embodiments, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NXT or NXS, wherein each X is independently H, K, L, or M.

[0291] In certain embodiments, N-glycosylated IL-21 comprises an N-glycosylation site with an amino acid sequence of NHT, NHS, NKT, NKS, NLT, NLS, NMT or NMS. In certain embodiments, N-glycosylated IL-21 comprises an N-glycosylation site with an amino acid sequence of NHT or NHS. In certain embodiments, N-glycosylated IL-21 comprises an N-glycosylation site with an amino acid sequence of NKT or NKS. In certain embodiments, N-glycosylated IL-21 comprises an N-glycosylation site with an amino acid sequence of NLT or NLS. In certain embodiments, N-glycosylated IL-21 comprises an N-glycosylation site with an amino acid sequence of NMT or NMS.

[0292] In one embodiment, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NHT or NHS, the N-glycosylation site starting at position 5 in the amino acid sequence of SEQ ID NO: 97. In another embodiment, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NMT or NMS, the N-glycosylation site starting at position 9 in the amino acid sequence of SEQ ID NO: 97. In yet another embodiment, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NLT or NLS, the N-glycosylation site starting at position 73 in the amino acid sequence of SEQ ID NO: 97. In yet another embodiment, the N-glycosylated IL-21 comprises an N-glycosylation site having an amino acid sequence of NKT or NKS, the N-glycosylation site starting at position 76 in the amino acid sequence of SEQ ID NO: 97.

[0293] In one embodiment, the N-glycosylated IL-21 comprises the amino acid substitution R5N, wherein the asparagine at position 5 is N-glycosylated. In another embodiment, the N-glycosylated IL-21 comprises the amino acid substitution R9N, wherein the asparagine at position 9 is N-glycosylated. In yet another embodiment, the N-glycosylated IL-21 comprises the amino acid substitution K73N, wherein the asparagine at position 73 is N-glycosylated. In yet another embodiment, the N-glycosylated IL-21 comprises the amino acid substitution R76N, wherein the asparagine at position 76 is N-glycosylated. In certain embodiments, the N-glycosylated IL-21 has an amino acid sequence of any one of SEQ ID NOs: 160 to 167.

[0294] In one embodiment, the N-glycosylated IL-21 has one glycan. In another embodiment, the N-glycosylated IL-21 has one glycan attached to the nitrogen atom in the side chain of an asparagine residue.

[0295] In one embodiment, N-glycosylated IL-21 has two glycans. In another embodiment, N-glycosylated IL-21 has two glycans, at least one of which is attached to a nitrogen atom in the side chain of an asparagine residue. In yet another embodiment, N-glycosylated IL-21 has two glycans, each of which is attached to a nitrogen atom in the side chain of an asparagine residue.

[0296] In one embodiment, the N-glycosylated IL-21 has three glycans. In one embodiment, the glycan is an N-glycan.

[0297] In one embodiment, the N-glycans on the N-glycosylated IL-21 are oligomannose type. In another embodiment, the N-glycans on the N-glycosylated IL-21 are complex type. In another embodiment, the N-glycans on the N-glycosylated IL-21 are hydride type.

[0298] In one embodiment, the N-glycans on the N-glycosylated IL-21 are biantennary complex. In another embodiment, the N-glycans on the N-glycosylated IL-21 are triantennary complex. In yet another embodiment, the N-glycans on the N-glycosylated IL-21 are tetraantennary complex.

[0299] In one embodiment, the N-glycan on the N-glycosylated IL-21 is one of the glycans described in Szabo et al., J. Proteome. Res., 2018, Vol. 17, pp. 1559-1574, the disclosure of which is incorporated herein by reference in its entirety.

[0300] In certain embodiments, IL-21 further comprises one or more additional substitutions, deletions, and / or insertions; and / or one or more additional post-translational modifications.

[0301] In certain embodiments, the fusion proteins provided herein have a binding dissociation constant for human IL-21Rα of SEQ ID NO: 167 ranging from about 1 pM to about 200 nM, about 10 pM to about 100 nM, about 20 pM to about 50 nM, or about 50 pM to about 20 nM.

[0302] In certain embodiments, the second polypeptide is fused to the N-terminus of the first polypeptide comprising an anti-albumin sdAb portion. In certain embodiments, the second polypeptide is fused to the C-terminus of the first polypeptide. In certain embodiments, the second polypeptide is fused to the N-terminus and C-terminus of the first polypeptide. In certain embodiments, the first polypeptide is fused to the N-terminus and C-terminus of the second polypeptide.

[0303] In certain embodiments, the second polypeptide is fused to the first polypeptide via a first linker. In certain embodiments, the first linker is a peptide linker. In certain embodiments, the first linker is cleavable. In certain embodiments, the first linker is a matrix metalloproteinase, legumin, protease or urokinase sensitive linker. In certain embodiments, the first linker is selected from SEQ ID NOs:73-91. In certain embodiments, the first linker is non-cleavable. In certain embodiments, the first linker is selected from GSG and SEQ ID NOs:58-72.

[0304] In certain embodiments, the anti-albumin construct comprises a) a first polypeptide comprising an anti-albumin sdAb portion; b) a second polypeptide, wherein the second polypeptide is fused to the first polypeptide ("second peptide-ALBM"); and c) a third polypeptide fused to the second peptide-ALBM.

[0305] In certain embodiments, the anti-albumin construct comprises a) a first polypeptide comprising an anti-albumin sdAb portion; b) a second polypeptide comprising a cytokine, wherein the second polypeptide is fused to the first polypeptide ("cytokine-ALBM"); and c) a third polypeptide fused to the cytokine-ALBM. In certain embodiments, the cytokine is selected from IL-21, IL-7, IL-15, IL-15 bound to IL-15Rα or a fragment thereof, IL-33, and IL-22. In certain embodiments, the third polypeptide comprises an antigen binding portion. In certain embodiments, the antigen is a tumor antigen. In certain embodiments, the antigen is selected from mesothelin ("MSLN"), GPA33, Her-2, EGFR, and CD20. In certain embodiments, the tumor antigen is selected from CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA, and BCMA. In certain embodiments, the third polypeptide comprises a second cytokine. In certain embodiments, the first cytokine and the second cytokine are each independently selected from IL-7, IL-15, IL-15 bound to IL-15Rα or a fragment thereof, and IL-21.

[0306] In certain embodiments, the anti-albumin construct comprises a) a first polypeptide comprising an anti-albumin sdAb portion; b) a second polypeptide comprising an antigen binding portion, wherein the second polypeptide is fused to the first polypeptide ("ABM-ALBM"); and c) a third polypeptide fused to the ABM-ALBM. In certain embodiments, the antigen is a tumor antigen. In certain embodiments, the antigen is selected from mesothelin ("MSLN"), GPA33, Her-2, EGFR, and CD20. In certain embodiments, the tumor antigen is selected from CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA, and BCMA. In certain embodiments, the third polypeptide comprises a second antigen binding portion. In certain embodiments, the second antigen is a tumor antigen. In certain embodiments, the third polypeptide comprises an imaging agent. In certain embodiments, the third polypeptide comprises a cytokine. In certain embodiments, the cytokine is selected from IL-21, IL-7, IL-15, IL-15 bound to IL-15Rα or a fragment thereof, IL-33, and IL-22.

[0307] In certain embodiments, the second polypeptide is fused to the N-terminus of the first polypeptide. In certain embodiments, the second polypeptide is fused to the C-terminus of the first polypeptide. In certain embodiments, the second polypeptide is fused to the N-terminus and C-terminus of the first polypeptide. In certain embodiments, the first polypeptide is fused to the N-terminus and C-terminus of the second polypeptide. In certain embodiments, the second polypeptide is fused to the first polypeptide via a first joint as described herein. In certain embodiments, the third polypeptide is fused to the N-terminus of the second peptide-ALBM. In certain embodiments, the third polypeptide is fused to the C-terminus of the second peptide-ALBM. In certain embodiments, the third polypeptide is fused to the N-terminus and C-terminus of the second peptide-ALBM. In certain embodiments, the second peptide-ALBM is fused to the N-terminus and C-terminus of the third polypeptide. In certain embodiments, the third polypeptide is fused to the second peptide-ALBM via a second joint. In certain embodiments, the second joint is a peptide joint. In certain embodiments, the first joint is not cleavable and the second joint is cleavable. In certain embodiments, both the first joint and the second joint are not cleavable. In certain embodiments, both the first joint and the second joint are cleavable. In certain embodiments, the first linker and / or the second linker is a matrix metalloproteinase, legumin, protease, or urokinase sensitive linker. In certain embodiments, the first linker and / or the second linker are each independently selected from SEQ ID NOs:73-91. In certain embodiments, the first linker and / or the second linker are each independently selected from SEQ ID NOs:58-72. In certain embodiments, the first linker and / or the second linker are each independently selected from SEQ ID NOs:58-91.

[0308] In certain embodiments, the construct further comprises a signal peptide.

[0309] In one embodiment, the present invention provides a fusion protein comprising an interleukin-21 domain, a V H H single domain antibody domain and optionally a peptide linker; wherein the C-terminus of the interleukin-21 domain is linked directly or via the peptide linker to the N-terminus of the VHH single domain antibody domain.

[0310] In another embodiment, the present invention provides a fusion protein comprising an interleukin-21 domain having an amino acid sequence of any one of SEQ ID NOs: 97, 98, and 151 to 168; V HH single domain antibody domain having the amino acid sequence of SEQ ID NOs: 1 to 9, 45 to 53 and 105 to 115; and optionally a peptide linker having the amino acid sequence of GSG or SEQ ID NOs: 58 to 73; wherein the C-terminus of the interleukin-21 domain is directly or via the peptide linker linked to the N-terminus of the VHH single domain antibody domain.

[0311] Connectors

[0312] The above anti-albumin construct may comprise one or more linkers (such as the first linker and the second linker described above).

[0313] In certain embodiments, the first linker and / or the second linker is a peptide linker. The length, flexibility and / or other properties of the peptide linker used for the anti-albumin construct may have some influence on the following properties, including but not limited to affinity, specificity or avidity for one or more specific antigens or epitopes. For example, a longer peptide linker may be selected to ensure that two adjacent domains do not interfere with each other spatially. In some embodiments, the peptide linker comprises flexible residues (such as glycine and serine) so that adjacent domains are free to move relative to each other. For example, a glycine-serine doublet may be a suitable peptide linker.

[0314] The peptide linker can have any suitable length. In certain embodiments, the length of the peptide linker is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100 or more amino acids in any one. In certain embodiments, the length of the peptide linker is no more than about 100, 75, 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or less amino acids in any one. In certain embodiments, the length of the peptide linker is any of about 1 amino acid to about 10 amino acids, about 1 amino acid to about 20 amino acids, about 1 amino acid to about 30 amino acids, about 5 amino acids to about 15 amino acids, about 10 amino acids to about 25 amino acids, about 5 amino acids to about 30 amino acids, about 10 amino acids to about 30 amino acids in length, about 30 amino acids to about 50 amino acids, about 50 amino acids to about 100 amino acids, or about 1 amino acid to about 100 amino acids.

[0315] In certain embodiments, the first linker is about one to forty (such as one to thirty-five, one to thirty, one to twenty-five, one to twenty, four to twenty, or four to sixteen) amino acids in length.

[0316] In certain embodiments, the first linker and / or the second linker is a non-peptide linker.

[0317] Other linker considerations include effects on the physical or pharmacokinetic properties of the resulting compound, such as solubility, lipophilicity, hydrophilicity, hydrophobicity, stability (more or less stable as well as planned degradation), rigidity, flexibility, immunogenicity, modulation of antibody binding, ability to be incorporated into micelles or liposomes, etc.

[0318] 1. Peptide linker

[0319] The peptide linker may have a naturally occurring sequence or a non-naturally occurring sequence. For example, a sequence derived from the hinge region of a heavy chain antibody may be used as a linker. See, for example, WO 1996 / 34103.

[0320] The peptide linker can have any suitable length. In certain embodiments, the length of the peptide linker is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100 or more amino acids in any one. In certain embodiments, the length of the peptide linker is no more than about 100, 75, 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or less amino acids in any one. In certain embodiments, the length of the peptide linker is any of about 1 amino acid to about 10 amino acids, about 1 amino acid to about 20 amino acids, about 1 amino acid to about 30 amino acids, about 5 amino acids to about 15 amino acids, about 10 amino acids to about 25 amino acids, about 5 amino acids to about 30 amino acids, about 10 amino acids to about 30 amino acids in length, about 30 amino acids to about 50 amino acids, about 50 amino acids to about 100 amino acids, or about 1 amino acid to about 100 amino acids.

[0321] The basic technical feature of this peptide linker is that the peptide linker does not have any polymerization activity. The characteristics of peptide linkers, including not promoting secondary structure, are known in the art and are described in, for example, Dall'Acqua et al., Biochem., Vol. 37: pp. 9266-9273 (1998); Cheadle et al., Mol. Immunol., Vol. 29: pp. 21-30 (1992); Raag and Whitlow, FASEB, Vol. 9: pp. 73-80 (1995). With regard to "peptide linkers", a particularly preferred amino acid is Gly. In addition, peptide linkers that do not promote any secondary structure are preferred. The connection between the domains can be provided, for example, by genetic engineering. Methods for preparing fused and operably linked fusion protein components and expressing these components in mammalian cells or bacteria are well known in the art. See, e.g., WO 99 / 54440; Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY, 1989 and 1994 or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.

[0322] The peptide linker may be a stable linker that is not cleavable by proteases, particularly matrix metalloproteinases (MMPs).In certain embodiments, the linker is selected from GSG and SEQ ID NOs: 58-72.

[0323] In certain embodiments, the linker is cleavable. In certain embodiments, the linker is a matrix metalloproteinase, legumin, protease, or urokinase sensitive linker. In certain embodiments, the linker is selected from SEQ ID NOs: 73-91.

[0324] The linker can also be a flexible linker. Exemplary flexible linkers include glycine polymers (G) n , glycine-serine polymers (including, for example, (GS) n , (GSGS) n (SEQ ID NO:65), (GGSG) n (SEQ ID NO:66), (GGGGS) n(SEQ ID NO: 60), wherein n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured and can therefore be used as neutral tethers between components. Glycine enters significantly more phi-psi space than alanine and is much less restrictive than residues with longer side chains (see Scheraga, Rev. Computational Chem., Vol. 11: pp. 173-142 (1992)). One of ordinary skill will recognize that the design of an antibody fusion protein may include a fully or partially flexible linker, such that the linker may include a flexible linker portion and one or more portions that impart a less flexible structure to provide a desired antibody fusion protein structure.

[0325] 2. Non-peptide linkers

[0326] The coupling of the above components can be achieved by any chemical reaction that will bind the two molecules, as long as both components retain their respective activities, i.e., bind to cytokine receptors, albumin or target antigens, respectively. This connection may include a variety of chemical mechanisms, such as covalent binding, affinity binding, embedding, coordination binding and complexing. In certain embodiments, the binding is covalent binding. Covalent binding can be achieved by direct condensation of existing side chains or by incorporation of external bridging molecules. In this case, many divalent or multivalent linking agents can be used to couple protein molecules. For example, representative coupling agents may include organic compounds, such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzene and hexamethylenediamine. This enumeration is not intended to exhaustively list various coupling agents known in the art, but rather examples of more common coupling agents. See, e.g., Killen and Lindstrom, J. Immunol., Vol. 133: 2549-2553 (1984); Jansen et al., Immunol. Rev., Vol. 62: 185-216 (1982); Vitetta et al., Science, Vol. 238: 1098-1104 (1987).

[0327] Linkers useful in the present disclosure are described in the literature (see, for example, Ramakrishnan et al., Cancer Res., Vol. 44: pp. 201-208 (1984)), describing the use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). In certain embodiments, the non-peptide linkers used herein include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride); (ii) SMPT (4-succinimidyloxycarbonyl-α-methyl-α-(2-pyridyl-dithio)-toluene (Pierce Chem. Co., catalog number 21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamido] hexanoate (Pierce Chem. Co., catalog number 21651G); (iv) sulfo-LC-SPDP (sulfosuccinimidyl 6 [3-(2-pyridyldithio)-propionamido] hexanoate (Pierce Chem. Co., catalog number 2165-G); and (v) sulfo-NHS (N-hydroxysulfo-succinimide (Pierce Chem. Co., catalog number 2165-G) conjugated to EDC. Chem. Co., catalog number 24510).

[0328] The components contained in the above-mentioned joints have different properties, so the fusion proteins may have different physicochemical properties. For example, the sulfo-NHS esters of alkyl carboxylic acids are more stable than the sulfo-NHS esters of aromatic carboxylic acids. The joints containing NHS-esters have lower solubility than sulfo-NHS esters. In addition, the joint SMPT contains a sterically hindered disulfide bond and can form an antibody fusion protein with increased stability. Disulfide bonds are generally more unstable than other bonds because disulfide bonds are cut in vitro, resulting in less available antibody fusion proteins. Sulfo-NHS can especially enhance the stability of carbodiimide conjugates. When carbodiimide conjugates (such as EDC) are used in combination with sulfo-NHS, an ester that is more resistant to hydrolysis than a separate carbodiimide coupling reaction is formed.

[0329] C. Anti-albumin construct variants

[0330] In certain embodiments, amino acid sequence variants of the anti-albumin constructs provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the anti-albumin construct in all or any of the components of the anti-albumin construct. The amino acid sequence variants of the anti-albumin construct may be prepared by introducing appropriate modifications into the nucleic acid sequence encoding the anti-albumin construct or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the anti-albumin construct. Any combination of deletions, insertions and substitutions may be performed to obtain the final construct, provided that the final construct has the desired characteristics.

[0331] 1. Substitutions, insertions, deletions and variants

[0332] In certain embodiments, anti-albumin construct variants having one or more amino acid substitutions are provided. The target sites for substitution mutagenesis include HVRs and FRs of the albumin binding molecule and / or antigen binding portion. Conservative substitutions are shown in Table 3. More substantial changes are provided under the heading "Exemplary Substitutions" and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the components of the anti-albumin constructs and screened for products having the desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0333] Table 3. Amino acid substitutions

[0334] Original residue Exemplary substitutions Preferred substitutions Ala(A) Val, Leu, Ile Val Arg(R) Lys, Gln, Asn Lys Asn(N) Gln, His, Asp, Lys, Arg Gln Asp(D) Glu, Asn Glu Cys(C) Ser, Ala Ser Gln(Q) Asn、Glu Asn Glu(E) Asp、Gln Asp Gly(G) Ala Ala His(H) Asn, Gln, Lys, Arg Arg Ile(I) Leu, Val, Met, Ala, Phe, norleucine Leu Leu(L) Norleucine, Ile, Val, Met, Ala, Phe Ile Lys(K) Arg, Gln, Asn Arg Met(M) Leu, Phe, Ile Leu Phe(F) Trp,Leu,Val,Ile,Ala,Tyr Tyr Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Val, Ser Ser Trp(W) Tyr、Phe Tyr Tyr(Y) Trp, Phe, Thr, Ser Phe Val(V) Ile, Leu, Met, Phe, Ala, norleucine Leu

[0335] Amino acids can be grouped according to common side chain properties:

[0336] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu and Ile;

[0337] (2) Neutral hydrophilic: Cys, Ser, Thr, Asn and Gln;

[0338] (3) Acidic: Asp and Glu;

[0339] (4) Basic: His, Lys and Arg;

[0340] (5) Residues that affect chain orientation: Gly and Pro; and

[0341] (6) Aromatic: Trp, Tyr and Phe.

[0342] Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.

[0343] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., humanized or human antibody). Typically, the resulting variant selected for further study will have modifications (e.g., improvements) relative to the parent antibody in certain biological properties (e.g., increased affinity and / or reduced immunogenicity) and / or will substantially retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity-matured antibodies, which can be conveniently produced, for example, using affinity maturation techniques based on phage display (such as those described herein). In short, one or more HVR residues are mutated, the variant antibodies are displayed on phage, and specific biological activities (e.g., binding affinity) are screened.

[0344] Changes (e.g., substitutions) can be made in HVRs, for example, to improve antibody affinity. Such changes can be made in HVR "hot spots", i.e., residues encoded by codons that undergo high frequency mutations during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol., Vol. 207: pp. 179-196 (2008), and / or SDRs (a-CDRs), and the resulting variants VH or VL are tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries has been described, e.g., Hoogenboom et al., Methods Mol.Biol., Vol. 178: pp. 1-37 (2001). In certain embodiments of affinity maturation, diversity is introduced into the variable gene selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variant with the desired affinity. Another method of introducing diversity involves an HVR directed method, in which several HVR residues (e.g., 4-6 residues at a time) are random. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 are particularly often targeted.

[0345] In certain embodiments, substitutions, insertions or deletions may occur within one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody to bind antigen. For example, conservative changes (e.g., conservative substitutions provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such changes may be outside of HVR "hot spots" or CDRs.

[0346] A useful method for identifying residues or regions of an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described in Cunningham and Wells, Science, Vol. 244: pp. 1081-1085 (1989). In this method, a residue or a group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at the amino acid position, indicating functional sensitivity to the initial substitution. Alternatively or additionally, the crystal structure of the antigen-antibody complex is used to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain desired properties.

[0347] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertion variants of antibody molecules include fusions of the N-terminus or C-terminus of an antibody with an enzyme (e.g., for ADEPT) or a polypeptide that increases the serum half-life of the antibody.

[0348] 2. Derivatives

[0349] In certain embodiments, the anti-albumin constructs provided herein may be further modified to contain additional non-proteinaceous moieties known in the art and readily available. Suitable portions for the derivatization of anti-albumin constructs include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), dextran or poly-(n-vinyl pyrrolidone) polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the anti-albumin construct may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the particular property or function of the anti-albumin construct to be improved, whether the anti-albumin construct derivative is to be used for treatment under defined conditions.

[0350] In certain embodiments, conjugates of anti-albumin constructs and non-protein moieties are provided that can be selectively heated by exposure to radiation. In certain embodiments, the non-protein moiety is a carbon nanotube. As described in Kam et al., Proc. Natl. Acad. Sci. USA, Vol. 102: pp. 11600-11605 (2005). The radiation can be of any wavelength and includes, but is not limited to, wavelengths that do not harm normal cells but heat the non-protein moiety to a temperature that kills cells in proximity to the non-protein moiety of the anti-albumin construct.

[0351] III. Pharmaceutical Compositions

[0352] The present disclosure also provides a pharmaceutical composition comprising any of the anti-albumin constructs described herein and an optional pharmaceutically acceptable carrier. The pharmaceutical composition can be prepared by mixing the anti-albumin constructs described herein having a desired purity with an optional pharmaceutically acceptable carrier, excipient or stabilizer (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)) in the form of a lyophilized preparation or an aqueous solution.

[0353] The pharmaceutical composition is preferably stable, wherein the anti-albumin construct described herein substantially maintains its physical and chemical stability and integrity during storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, pp. 247-301, Lee, ed., Marcel Dekker, Inc., New York, NY Press, 1991, and Jones, Adv. Drug Delivery Rev., Vol. 10: pp. 29-90 (1993). Stability can be measured at a selected temperature for a selected time period. For rapid screening, the formulation can be kept at 40°C for 2 weeks to 1 month, at which time the stability is measured. When the formulation is to be stored at 2-8°C, the formulation should generally be stable at 30°C or 40°C for at least 1 month, and / or stable at 2-8°C for at least 2 years. When the formulation is to be stored at 30°C, the formulation should generally be stable at 30°C for at least 2 years, and / or stable at 40°C for at least 6 months. For example, the degree of aggregation during storage can be used as an indicator of protein stability. In certain embodiments, a stable formulation of an anti-albumin construct described herein may comprise less than about 10% (preferably less than about 5%) of the anti-albumin construct present as aggregates in the formulation.

[0354] Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers; antioxidants including ascorbic acid, methionine, vitamin E, sodium metabisulfite; preservatives; isotonic agents (e.g., sodium chloride); stabilizers; metal complexes (e.g., Zn-protein complexes); chelating agents such as EDTA and / or nonionic surfactants.

[0355] Examples of physiologically acceptable carriers include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride or benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins; Proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN®. TM , polyethylene glycol (PEG) and PLURONICS TM or polyethylene glycol (PEG).

[0356] Buffers are used to control pH within a range that optimizes the therapeutic effect, especially when stability depends on pH. The buffer is preferably present in a concentration within the range of about 50 mM to about 250 mM. Buffers suitable for use in the present disclosure include organic and inorganic acids and salts thereof, such as citrates, phosphates, succinates, tartrates, fumarates, gluconates, oxalates, lactates, and acetates. In addition, the buffer may include histidine and trimethylamine salts such as Tris.

[0357] Preservatives are added to retard microbial growth, and these preservatives are typically present in the range of 0.2%-1.0% (w / v). The addition of preservatives can, for example, facilitate the production of multi-purpose (multiple dose) formulations. Preservatives suitable for use in the present disclosure include octadecyl dimethyl benzyl ammonium chloride; hexamethonium chloride; halogenated (e.g., chlorinated, brominated, iodinated) benzalkonium, benzethonium chloride; thimerosal, phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol, 3-pentanol and m-cresol.

[0358] There is a tonicity agent sometimes referred to as a "stabilizer" to adjust or maintain the tension of the liquid in the composition. When tonicity agents are used together with large charged biomolecules such as proteins and antibodies, they are generally referred to as "stabilizers" because they can interact with the charged groups of the amino acid side chains, thereby reducing the possibility of intermolecular and intramolecular interactions. Considering the relative amounts of other ingredients, the tonicity agent can be present in any amount between 0.1% by weight and 25% by weight, preferably between 1% by weight and 5% by weight. Preferred tonicity agents include polyols, preferably trivalent or more polyols, such as glycerol, erythritol, arabitol, xylitol, sorbitol and mannitol.

[0359] Additional excipients include agents that can serve as one or more of the following: (1) fillers, (2) solubilizers, (3) stabilizers, and (4) agents that prevent denaturation or adhesion to the walls of the container. Such excipients include: polyols (such as those listed above); amino acids such as alanine, glycine, glutamine, asparagine, histidine, arginine, lysine, ornithine, leucine, 2-phenylalanine, glutamic acid, and threonine; organic sugars or sugar alcohols such as sucrose, lactose, lactitol, trehalose, stachyose, mannose, sorbitol, xylose, ribose, ribitol, inositol, inositol, galactose, galactitol, glycerol, cyclitols (e.g., inositol), and polyethylene glycol. alcohol; sulfur-containing reducing agents such as urea, glutathione, lipoic acid, sodium thioacetate, thioglycerol, α-thioglycerol and sodium thiosulfate; low molecular weight proteins such as human serum albumin, bovine serum albumin, gelatin or other immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides (e.g., xylose, mannose, fructose and glucose); disaccharides (e.g., lactose, maltose and sucrose); trisaccharides such as raffinose; and polysaccharides such as dextrin or dextran.

[0360] A nonionic surfactant or detergent (also referred to as a "wetting agent") is present to help dissolve the therapeutic agent and protect the therapeutic protein from agitation-induced aggregation, which also allows the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody. The nonionic surfactant is present in a range of about 0.05 mg / mL to about 1 mg / mL, preferably about 0.07 mg / mL to about 0.2 mg / mL.

[0361] Suitable nonionic surfactants include polysorbate (20, 40, 60, 65 or 80), poloxamer (184 or 188), Polyols, Polyoxyethylene sorbitan monoether ( -20 or -80), lauromacrogol 400, polyoxyethylene 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 or 60, glycerol monostearate, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. Anionic detergents that can be used include sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.

[0362] In order to use the pharmaceutical compositions for in vivo administration, these pharmaceutical compositions must be sterile. The pharmaceutical compositions can be sterilized by filtration through a sterile filtration membrane. The pharmaceutical compositions herein are typically placed in a container with a sterile access port, such as an intravenous solution bag or a vial with a stopper pierced by a hypodermic needle.

[0363] The route of administration is according to known and recognized methods, such as by single or multiple boluses or infusions in a suitable manner over a longer period of time, for example, by injection or infusion by subcutaneous, intravenous, intraperitoneal, intramuscular, intraarterial, intralesional or intraarticular routes, topical application or inhalation by sustained release or delayed release means. In certain embodiments, the pharmaceutical composition is administered locally, such as intratumorally or intravitreally.

[0364] Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antagonist in the form of shaped articles, such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides (US 3,773,919), copolymers of L-glutamic acid and ethyl L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) and poly-D-(-)-3-hydroxybutyric acid.

[0365] The pharmaceutical composition herein may also contain more than one active compound necessary for treating a specific indication, preferably active compounds with complementary activities that do not adversely affect each other. Alternatively or additionally, the composition may include a cytotoxic agent, a chemotherapeutic agent, a cytokine, an immunosuppressant, or a growth inhibitor. Such molecules are appropriately combined in an amount effective for the intended purpose.

[0366] The active ingredient can also be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions or nanoparticles and nanocapsules), or in macroemulsions. These techniques are disclosed in "Remington's Pharmaceutical Sciences", 18th edition.

[0367] The anti-albumin constructs disclosed herein can be formulated as immunoliposomes. Liposomes containing anti-albumin constructs are prepared by methods known in the art, such as those described in Epstein et al., Proc. Natl. Acad. Sci. USA, Vol. 82: pp. 3688-3692 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, Vol. 77: pp. 4030-4034 (1980); US 4,485,045 and US 4,544,545. Liposomes with extended circulation time are disclosed in US 5,013,556.

[0368] Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and phosphatidylethanolamine derivatized with polyethylene glycol (PEG-PE).The liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.

[0369] In certain embodiments, the pharmaceutical composition is contained in a single-use vial, such as a single-use sealed vial. In certain embodiments, the pharmaceutical composition is contained in a vial for multiple uses. In certain embodiments, the pharmaceutical composition is contained in bulk in a container. In certain embodiments, the pharmaceutical composition is stored frozen.

[0370] IV. Treatment Methods

[0371] One aspect of the present disclosure provides methods of treating a disease or disorder in an individual using the anti-albumin constructs or pharmaceutical compositions described herein.

[0372] In certain embodiments, a method for treating a disease or condition in an individual is provided, comprising administering an effective amount of a construct or pharmaceutical composition as described herein to an individual. In certain embodiments, a method for treating a disease or condition in an individual is provided, comprising administering an effective amount of an anti-albumin construct to an individual, the anti-albumin construct comprising a first polypeptide and a second polypeptide, the first polypeptide comprising an anti-albumin sdAb portion, wherein the second polypeptide comprises a therapeutic agent. In certain embodiments, the therapeutic agent comprises an antigen binding portion (such as an antibody or fragment thereof bound to a tumor antigen). In certain embodiments, the antigen is a tumor antigen. In certain embodiments, the tumor is a solid tumor. In certain embodiments, the tumor is a liquid tumor. In certain embodiments, the tumor antigen is selected from mesothelin ("MSLN"), GPA33, Her-2, EGFR, CD20, CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA and BCMA. In certain embodiments, the agent is an immune checkpoint protein. In certain embodiments, the therapeutic agent includes a cytokine. In certain embodiments, the cytokine is selected from IL-21, IL-7, IL-15, IL-15 bound to IL-15Rα or a fragment thereof, IL-33, and IL-22.

[0373] Disease or condition

[0374] The methods described herein can be used to treat a disease or condition. In certain embodiments, the disease or condition is cancer, an inflammatory disorder or an infection.

[0375] In certain embodiments, the disease or disorder is an inflammatory disease. In certain embodiments, the disease is selected from ulcerative colitis, Crohn's disease, or ulcerative ileitis, and intestinal graft-versus-host disease.

[0376] In certain embodiments, the disease or condition is cancer. In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a liquid tumor. In certain embodiments, the cancer is selected from mesothelioma, lung cancer, breast cancer, ovarian cancer, pancreatic cancer, lymphoma (non-Hodgkin's lymphoma), leukemia (such as acute myeloid leukemia), head and neck cancer, liver cancer, kidney cancer, renal cancer, esophageal cancer, gastric cancer and colorectal cancer. In certain embodiments, the cancer is selected from mesothelioma, lung cancer, ovarian cancer and gastric cancer.

[0377] Combination therapy

[0378] In certain embodiments, the method further comprises administering a second agent. In certain embodiments, the second agent comprises a therapeutic antibody, an immune checkpoint inhibitor, a second cytokine, a chemotherapeutic agent, a tyrosine kinase inhibitor, or an immune cell.

[0379] In certain embodiments, the second agent is a therapeutic antibody. In certain embodiments, the therapeutic antibody binds to a tumor antigen. In certain embodiments, the tumor antigen is selected from mesothelin, GPA33, Her-2, EGFR, and CD20. In certain embodiments, the tumor antigen is selected from CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA, and BCMA.

[0380] In certain embodiments, the tumor antigen is mesothelin. In certain embodiments, the second agent is an anti-mesothelin antibody or fragment thereof. In certain embodiments, the anti-mesothelin antibody or fragment thereof comprises a single chain antibody comprising an anti-mesothelin heavy chain variable region (anti-MSLN V H ), wherein the anti-MSLN V H Comprising CDR1, CDR2 and CDR3, wherein: a) CDR1 comprising the amino acid sequence of SEQ ID NO: 92, CDR2 comprising the amino acid sequence of SEQ ID NO: 93, and CDR3 comprising the amino acid sequence of SEQ ID NO: 94, or variants comprising a total of up to 3, 2 or 1 amino acid substitutions in the CDRs; or b) CDR1 comprising the amino acid sequence of SEQ ID NO: 95, CDR2 comprising the amino acid sequence of SEQ ID NO: 96, and CDR3 comprising the amino acid sequence of GRY, or variants thereof comprising a total of up to 3, 2 or 1 amino acid substitutions in the CDRs.

[0381] In certain embodiments, the second agent is an immune checkpoint regulator. In certain embodiments, the immune checkpoint regulator is an inhibitor of an immune checkpoint protein selected from PD-L1, CTLA4, PD-L2, PD-1, CD47, albumin, GITR, TIM3, LAG3, CD27 and B7H4.

[0382] In certain embodiments, the immune checkpoint protein is PD- 1. In certain embodiments, the second agent is an anti-PD-1 antibody or a fragment thereof.

[0383] In certain embodiments, the second agent is a second cytokine. In certain embodiments, the cytokine in the anti-albumin construct is IL-21, and wherein the second cytokine is selected from IL-7, IL-15, and IL-15 bound to IL-15Rα or a variant thereof with an extended half-life.

[0384] In certain embodiments, the second agent is an immune cell. In certain embodiments, the immune cell includes a T cell or a NK cell. In certain embodiments, the immune cell includes a T cell expressing a chimeric antigen receptor (CAR), a T cell expressing a modified T cell receptor (TCR), or a T cell isolated from a tumor.

[0385] In certain embodiments, the second agent is a tyrosine kinase inhibitor.

[0386] In certain embodiments, the second agent is a chemotherapeutic agent (such as sorafenib).

[0387] Dosage regimen

[0388] The anti-albumin construct and / or the second agent can be administered to the individual using any suitable dose and route of administration. In certain embodiments, the anti-albumin construct and / or the second agent is administered to the individual parenterally. The route of administration is according to known and recognized methods, such as by single or multiple boluses or infusions over a period of time in a suitable manner, for example, by injection or infusion by subcutaneous, intravenous, intraperitoneal, intramuscular, intraarterial, intralesional, intraarticular, intratumoral, or oral routes.

[0389] In certain embodiments, the anti-albumin construct and the second agent are administered to the subject simultaneously, concurrently, or sequentially.

[0390] Determining the appropriate dosage or route of administration is well known to those of ordinary skill in the art. Animal experiments provide reliable guidance for determining effective doses for human diagnostic applications. Interspecies scaling of effective doses can be performed according to the principles of "The Use of Interspecies Scaling in Toxicokinetics" formulated by Mordenti and Chappell in Toxicokinetics and New Drug Development, Yacobi et al., eds., Pergamon Press, New York, 1989, pp. 42-46.

[0391] In certain embodiments, the anti-albumin construct is administered at a frequency of about once every three weeks to about twice a week, such as about once every three weeks to about once every two weeks, about once every two weeks to about once a week, or about once a week to about twice a week. In certain embodiments, the anti-albumin construct is administered at a frequency of no less than about once every three weeks, about once every two weeks, about once a week, or about twice a week. In certain embodiments, the anti-albumin construct is administered at a frequency of no more than about once every three weeks, about once every two weeks, about once a week, or about twice a week. In certain embodiments, the anti-albumin construct is administered at a frequency of about once every three weeks, about once every two weeks, about once a week, or about twice a week.

[0392] In certain embodiments, the anti-albumin construct is administered for at least about one week to six months (such as one week to two weeks, three weeks, or four weeks, one week to one month, two months, three months, four months, five months, or six months, one month to two months, three months, four months, five months, or six months, three months to four months, five months, or six months) per treatment cycle.

[0393] In certain embodiments, the amount of the anti-albumin construct administered per administration is from about 100 ng / kg to about 10 mg / kg (e.g., from about 100 ng / kg to about 500 ng / kg, from about 500 ng / kg to about 1 μg / kg, from about 1 μg / kg to about 5 μg / kg, from about 5 μg / kg to about 10 μg / kg, from about 10 μg / kg to about 50 μg / kg, from about 50 μg / kg to about 100 μg / kg, from about 100 μg / kg to about 500 μg / kg, from about 500 μg / kg to about 1 mg / kg, from about 1 mg / kg to about 5 mg / kg, or from about 5 mg / kg to about 10 mg / kg).

[0394] In certain embodiments, the second agent (such as a therapeutic antibody that binds to mesothelin or an inhibitor of PD-1) is administered at a frequency of about once a month to about twice a week (such as about once a month to twice a month, three times a month, or four times a month, about once every two weeks, about once every three weeks, about once a week, or twice a week).

[0395] In certain embodiments, the amount of the second agent (such as a therapeutic antibody that binds to mesothelin or an inhibitor of PD-1) administered per administration is from about 100 ng / kg to about 100 mg / kg (e.g., from about 100 ng / kg to about 500 ng / kg, from about 500 ng / kg to about 1 μg / kg, from about 1 μg / kg to about 5 μg / kg, from about 5 μg / kg to about 10 μg / kg, from about 10 μg / kg to about 50 μg / kg, from about 50 μg / kg to about 100 μg / kg, from about 100 μg / kg to about 500 μg / kg, from about 500 μg / kg to about 1 mg / kg, from about 1 mg / kg to about 5 mg / kg, from about 5 mg / kg to about 10 mg / kg, from about 10 mg / kg to about 50 mg / kg, or from about 50 mg / kg to about 100 mg / kg).

[0396] VI. Preparation Method

[0397] The anti-albumin constructs described herein can be prepared using any method known in the art or as described herein. See, for example, Examples 1-5. In certain embodiments, a method for producing an anti-albumin construct is provided, the method comprising: (a) culturing a host cell comprising an isolated nucleic acid or vector encoding an anti-albumin construct described herein under conditions effective to express the encoded anti-albumin construct; and (b) obtaining the expressed anti-albumin construct from the host cell. In certain embodiments, the method of step (a) further comprises producing a host cell comprising an isolated nucleic acid or vector encoding an anti-albumin construct described herein.

[0398] Methods for preparing sdAbs have been described. See, for example, Els Pardon et al., Nat. Protoc., Vol. 9: 674-693 (2014). sdAbs (such as V H H) can be obtained using methods known in the art, such as by immunizing a Camelidae species (such as a camel or llama) and obtaining hybridomas therefrom, or by cloning a single domain antibody library by using molecular biology techniques known in the art and subsequent selection by ELISA using individual clones of an unselected library or by using phage display.

[0399] In order to recombinantly produce sdAb, nucleic acid encoding a single domain antibody is isolated and inserted into a replicable vector for further cloning (DNA amplification) or expression. DNA encoding a single domain antibody is easily isolated and sequenced using conventional methods (e.g., by using oligonucleotide probes that can specifically bind to genes encoding antibody heavy and light chains). Many vectors are available. The selection of vectors depends in part on the host cell used. Typically, preferred host cells are prokaryotic or eukaryotic (usually mammalian) origin. In certain embodiments, the isolated nucleic acid encoding an anti-albumin construct described herein comprises a nucleic acid sequence encoding any one of SEQ ID NOs: 1-9, 45-53, 99-101, 103-115, 149 and 150.

[0400] 1. Recombinant Production in Prokaryotic Cells

[0401] a) Vector construction

[0402] The polynucleotide sequences encoding the antibodies of the present disclosure can be obtained using standard recombinant techniques. The desired polynucleotide sequences can be isolated and sequenced from antibody-producing cells (such as hybridoma cells). Alternatively, polynucleotides can be synthesized using a nucleotide synthesizer or PCR technology. Once the sequence encoding the polypeptide is obtained, it is inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in a prokaryotic host. Many vectors available and known in the art can be used for the purposes of the present disclosure. The selection of suitable vectors depends primarily on the size of the nucleic acid to be inserted into the vector and the specific host cell to be transformed with the vector. Each vector contains a variety of components, depending on the function of the vector (amplification and / or expression of heterologous polynucleotides) and the compatibility of the vector with the specific host cell in which it is located. Vector components typically include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, a heterologous nucleic acid insert, and a transcription termination sequence.

[0403] Generally, plasmid vectors containing replicon and control sequences derived from species compatible with the host cell are used in conjunction with these hosts. The vectors usually carry a replication site as well as a marker sequence capable of providing phenotypic selection in transformed cells.

[0404] In addition, phage vectors containing replicons and control sequences compatible with the host microorganisms can be used as transformation vectors associated with these hosts. For example, phage (such as GEMTM-11) can be used to prepare recombinant vectors, which can be used to transform susceptible host cells (such as E. coli LE392).

[0405] The expression vector of the present disclosure may comprise two or more promoter-cistron pairs of each component in the encoded polypeptide component. A promoter is a non-translated regulatory sequence located upstream (5') of a cistron that regulates the expression of the cistron. Prokaryotic promoters are generally divided into two categories, inducible and constitutive. An inducible promoter is a promoter that increases the transcription level of a cistron under its control in response to changes in culture conditions (e.g., the presence or absence of nutrients or changes in temperature).

[0406] A large number of promoters recognized by a variety of potential host cells are well known. Promoters can be removed from source DNA by restriction enzyme digestion and the promoter sequence of separation is inserted into the carrier of the present disclosure, and the selected promoter is operably connected to the cistron DNA encoding light chain or heavy chain. Natural promoter sequences and many heterologous promoters can be used for instructing the amplification and / or expression of target gene. In certain embodiments, heterologous promoters are used because they usually allow higher transcription and higher yield of expressed target gene compared with natural target polypeptide promoters.

[0407] Promoters suitable for prokaryotic hosts include PhoA promoter, galactanase and lactose promoter systems, tryptophan (trp) promoter systems, and hybrid promoters (such as tac or trc promoters). However, other promoters that function in bacteria (such as other known bacterial or phage promoters) are also suitable. The nucleic acid sequences of these promoters have been published, so that the technician can use a linker or adapter to operably connect them to the cistron encoding the target light chain and heavy chain to provide any desired restriction sites. Siebenlist et al., Cell, Vol. 20: pp. 269-281 (1980).

[0408] In one aspect, each cistron in the recombinant vector comprises a secretory signal sequence component that instructs the transmembrane transport of the expressed polypeptide. Generally, the signal sequence can be a component of the vector or a part of the target polypeptide DNA inserted into the vector. The signal sequence selected for the purpose of the present disclosure should be a signal sequence recognized and processed (i.e., cut by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and do not process the natural signal sequence of a heterologous polypeptide, the signal sequence is replaced by a prokaryotic signal sequence, which is selected from, for example, alkaline phosphatase, penicillinase, Ipp or heat-stable enterotoxin II (STII) leader sequence, LamB, PhoE, PelB, OmpA and MBP. In certain embodiments of the present disclosure, the signal sequence of the two cistrons used for the expression system is an STII signal sequence or a variant thereof.

[0409] In certain embodiments, production of anti-albumin constructs according to the present disclosure can be performed in the cytoplasm of the host cell and therefore does not require the presence of a secretion signal sequence within each cistron. In certain embodiments, the polypeptide component (such as a V encoding a second antigen binding moiety optionally fused to a first antigen binding moiety) is H A polypeptide comprising a structural domain and a V domain encoding a second antigen binding moiety optionally fused to a first antigen binding moiety L The polypeptides of the structural domains are expressed, folded and assembled to form functional antibodies in the cytoplasm. Certain host strains (e.g., E. coli trxB- strains) provide cytoplasmic conditions that are favorable for disulfide bond formation, thereby allowing the correct folding and assembly of the expressed protein subunits. Proba and Pluckthun, Gene, Vol. 159: pp. 203-207 (1995).

[0410] The present disclosure provides expression systems in which the quantitative ratio of expressed polypeptide components can be adjusted to maximize the yield of secreted and properly assembled antibodies of the present disclosure. This regulation is achieved at least in part by simultaneously regulating the translation strength of the polypeptide components. A technique for regulating translation strength is disclosed in US 5,840,523. This technique utilizes variants of the translation initiation region (TIR) ​​within a cistron. For a given TIR, a series of amino acid or nucleic acid sequence variants with a certain range of translation strengths can be generated, thereby providing a convenient means of regulating this factor to obtain the desired expression level of a particular chain. TIR variants can be generated by conventional mutagenesis techniques that result in codon changes that can change the amino acid sequence, although silent changes in the nucleic acid sequence are preferred. Changes in TIR can include, for example, changes in the number or spacing of Shine-Dalgarno sequences, as well as changes in signal sequences. One method for generating mutant signal sequences is to generate a "codon library" at the beginning of a coding sequence that does not change the amino acid sequence of the signal sequence (i.e., the change is silent). This can be achieved by changing the third nucleotide position of each codon; in addition, some amino acids (such as leucine, serine, and arginine) have multiple first and second positions, which can increase the complexity of making libraries.

[0411] Preferably, a set of vectors is generated in which each cistron has a range of TIR strengths. This limited set provides a comparison of the expression level of each chain and the yield of the desired protein product under various TIR strength combinations. The TIR strength can be determined by quantitative reporter gene expression levels, as described in detail in US 5,840,523. Based on the translation strength comparison, the desired individual TIRs are selected for combination in the expression vector constructs of the present invention.

[0412] b) Prokaryotic host cells

[0413] Prokaryotic host cells suitable for expressing antibodies of the present disclosure include archaea and true bacteria, such as gram-negative or gram-positive organisms. Examples of useful bacteria include Escherichia (e.g., Escherichia coli), Bacillus (e.g., Bacillus subtilis), Enterobacter, Pseudomonas (e.g., Pseudomonas aeruginosa), Salmonella typhimurium, Serratia marcescens, Klebsiella, Proteus, Shigella, Rhizobium, Vitreoscilla or Paracoccus. In certain embodiments, gram-negative cells are used. In certain embodiments, Escherichia coli cells are used as hosts. Examples of Escherichia coli strains include strain W3110 and derivatives thereof, including strains having the genotype W3110 AfhuA (AtonA) ptr3 lac Iq lacL8AompT A (nmpc-fepE) degP41 kan RThe strain 33D3 (US 5,639,635) of Escherichia coli is also suitable. Other strains and derivatives thereof, such as Escherichia coli 294 (ATCC 31,446), Escherichia coli B, Escherichia coli 1776 (ATCC 31,537) and Escherichia coli RV308 (ATCC 31,608) are also suitable. These examples are illustrative and not restrictive. It is generally necessary to consider the reproducibility of the replicon in the bacterial cell to select a suitable bacterium. For example, when the replicon is provided using a known plasmid such as pBR322, pBR325, pACYC177 or pKN410, Escherichia coli, Serratia or Salmonella species can be suitably used as a host.

[0414] Generally, the host cells should secrete minimal amounts of proteolytic enzymes, and it may be desirable to incorporate additional protease inhibitors into the cell culture.

[0415] c) Protein production

[0416] Host cells are transformed with the above expression vectors and cultured in conventional nutrient media modified by the presence of inducible promoters, selection of transformants or amplification of genes encoding the desired sequence. Transformation refers to the introduction of DNA into a prokaryotic host so that the DNA can be replicated as an extrachromosomal element or by a chromosomal integrant. Depending on the host cell used, standard techniques suitable for such cells are used for transformation. Calcium treatment using calcium chloride is commonly used for bacterial cells containing a large amount of cell wall barriers. Another method of transformation uses polyethylene glycol / DMSO. Another technique used is electroporation.

[0417] Prokaryotic cells used to produce antibodies of the present disclosure are grown in culture media known in the art and suitable for culturing the selected host cells. Examples of suitable culture media include Luria broth (LB) plus essential nutrient supplements. In certain embodiments, the culture media also contains a selection agent that is selected based on the construction of the expression vector to selectively allow the growth of prokaryotic cells containing the expression vector. For example, ampicillin is added to the culture media to grow cells expressing an ampicillin resistance gene.

[0418] Any necessary supplements other than carbon, nitrogen and inorganic phosphate sources can also be introduced separately or as a mixture (such as a complex nitrogen source) with another supplement or culture medium at appropriate concentrations. Optionally, the culture medium may contain one or more reducing agents selected from glutathione, cysteine, cystamine, thioglycolate, dithioerythritol and dithiothreitol. Prokaryotic host cells are cultured at a suitable temperature. For example, for E. coli growth, the preferred temperature range is from about 20°C to about 39°C, more preferably from about 25°C to about 37°C, even more preferably about 30°C. The pH of the culture medium can be any pH in the range of about 5 to about 9, which depends primarily on the host organism. For E. coli, the pH is preferably from about 6.8 to about 7.4, more preferably about 7.0.

[0419] If an inducible promoter is used in the expression vector of the present disclosure, protein expression is induced under conditions suitable for activating the promoter. In one aspect of the present disclosure, the PhoA promoter is used to control transcription of the polypeptide. Therefore, the transformed host cells are cultured in a phosphate-limited medium for induction. Preferably, the phosphate-limited medium is CRAP medium. A variety of other inducers may be used, as known in the art, depending on the vector construct used.

[0420] The expressed anti-albumin constructs of the present disclosure are secreted into and recovered from the periplasm of the host cells. Protein recovery typically involves disrupting the microorganism, typically by means such as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris or whole cells may be removed by centrifugation or filtration. The protein may be further purified, for example, by affinity resin chromatography. Alternatively, the protein may be transported to a culture medium and separated therein. The cells may be removed from the culture, and the culture supernatant may be filtered and concentrated to further purify the produced protein. The expressed polypeptide may be further isolated and identified using generally well-known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot analysis.

[0421] Alternatively, a large amount of protein production is carried out by fermentation process. Various large-scale fed-batch fermentation methods can be used for producing recombinant proteins. Large-scale fermentation has a capacity of at least 1,000 liters, preferably a capacity of about 1,000 to 100,000 liters. These fermentation tanks use agitator impellers to distribute oxygen and nutrients, especially glucose (preferred carbon / energy). Small-scale fermentation generally refers to the fermentation in a fermentation tank where the volume capacity is no more than about 100 liters and the scope can be about 1 liter to about 100 liters.

[0422] During fermentation, cells are usually grown under appropriate conditions to a desired density, such as OD 550Induction of protein expression begins after about 180-220 hours (at this stage the cells are in the early stationary phase). A variety of inducers can be used depending on the vector construct used, as known in the art and described above. The cells can be grown for a shorter period of time before induction. The cells are typically induced for about 12-50 hours, although longer or shorter induction times can be used.

[0423] To improve the production yield and quality of the antibodies of the present disclosure, various fermentation conditions can be improved. For example, to improve the correct assembly and folding of secreted polypeptides, additional vectors that overexpress chaperone proteins, such as Dsb proteins (DsbA, DsbB, DsbC, DsbD and / or DsbG) or FkpA (a peptidyl prolyl cis-trans isomerase with chaperone activity), can be used to co-transform host prokaryotic cells. Chaperone proteins have been shown to facilitate the proper folding and solubility of heterologous proteins produced in bacterial host cells.

[0424] In order to minimize proteolysis of expressed heterologous proteins, especially those that are sensitive to proteolysis, certain host strains lacking proteolytic enzymes can be used in the present invention. For example, the host cell strain can be modified to generate genetic mutations in genes encoding known bacterial proteases, such as Protease III, OmpT, DegP, Tsp, Protease I, Protease Mi, Protease V, Protease VI, and combinations thereof.

[0425] E. coli strains lacking proteolytic enzymes and transformed with plasmids overexpressing one or more chaperone proteins can be used as host cells in expression systems encoding antibodies of the disclosure.

[0426] d) Protein purification

[0427] The anti-albumin constructs produced herein are further purified to obtain substantially homogeneous preparations for further assays and use. Standard protein purification methods known in the art can be used. The following methods are examples of suitable purification methods: immunoaffinity column or ion exchange column fractionation, ethanol precipitation, reverse phase HPLC, silica or cation exchange resin (such as DEAE) chromatography, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation and gel filtration using, for example, Sephadex G-75.

[0428] In certain embodiments, protein A immobilized on a solid phase is used for immunoaffinity purification of antibodies comprising an Fc region of the present disclosure. Protein A is a 41 kD cell wall protein from Staphylococcus aureus that binds to the Fc region of antibodies with high affinity. Lindmark et al., J. Immunol. Meth., Vol. 62: pp. 1-13 (1983). The solid phase to which protein A is immobilized is preferably a column comprising a glass or silica surface, more preferably a controlled pore glass column or a silicic acid column. In some applications, the column has been coated with a reagent (such as glycerol) to prevent nonspecific adhesion of contaminants. The solid phase is then washed to remove contaminants that are nonspecifically bound to the solid phase. Finally, the antibody of interest is recovered from the solid phase by elution.

[0429] 2. Recombinant Production in Eukaryotic Cells

[0430] For eukaryotic expression, vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

[0431] a) Signal sequence components

[0432] Vectors for eukaryotic hosts may also be inserts encoding signal sequences or other polypeptides having specific cleavage sites at the N-terminus of mature proteins or polypeptides. The heterologous signal sequence selected is preferably a signal sequence that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. In mammalian cell expression, mammalian signal sequences and viral secretory leaders (e.g., herpes simplex gD signal) are available.

[0433] The DNA of this precursor region is linked in reading frame to the DNA encoding the antibody of the present invention.

[0434] b) Origin of replication

[0435] Typically, mammalian expression vectors do not require an origin of replication component (the SV40 origin is often used only because it contains the early promoter).

[0436] c) Selecting genomic components

[0437] Expression and cloning vectors may contain selection genes, also known as selectable markers. Typical selection genes encode: (a) proteins that confer resistance to antibiotics or other toxins, such as ampicillin, neomycin, methotrexate, or tetracycline; (b) proteins that complement auxotrophic deficiencies; or (c) proteins that provide critical nutrients that cannot be obtained from complex media, such as the gene encoding Bacillus D-alanine racemase.

[0438] An example of a selection scheme utilizes a drug to prevent the growth of host cells. Those cells that are successfully transformed with a heterologous gene produce a protein that confers drug resistance and thus survive the selection scheme. Examples of this dominant selection use the drugs sinocycline, mycophenolic acid, and hygromycin.

[0439] Another example of a suitable selectable marker for mammalian cells is one that enables the identification of cells competent to take up nucleic acid encoding an antibody of the disclosure, such as DHFR, thymidine kinase, metallothionein-I and metallothionein-II (preferably primate metallothionein genes), adenosine deaminase, or ornithine decarboxylase.

[0440] For example, cells transformed with the DHFR selection gene are first identified by culturing all transformants in a medium containing methotrexate (Mtx), a competitive antagonist of DHFR. When wild-type DHFR is used, a suitable host cell is a Chinese hamster ovary (CHO) cell line (e.g., ATCC CRL-9096) lacking DHFR activity.

[0441] Alternatively, host cells (particularly wild-type hosts containing endogenous DHFR) transformed or co-transformed with a DNA sequence encoding a polypeptide, a wild-type DHFR protein, and another selectable marker, such as aminoglycoside 3'-phosphotransferase (APH), can be selected by growing the cells in a medium containing a selection agent for the selectable marker, such as an aminoglycoside antibiotic (e.g., kanamycin, neomycin, or G418).

[0442] d) Promoter components

[0443] Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably connected to the nucleic acid of the desired polypeptide sequence of the encoding. In fact, all eukaryotic genes have an AT-rich region located about 25 to 30 bases upstream of the transcription initiation site. Another sequence found at 70 to 80 bases upstream of many gene transcription initiations is the CNCAAT district, in which N can be any nucleotide. The 3' end of most eukaryotic organisms is the AATAAA sequence, which can be a signal that the polyA tail is added to the 3' end of the encoding sequence. All of these sequences can be inserted into the eukaryotic expression vector.

[0444] Other promoters suitable for use with prokaryotic hosts include the phoA promoter, lactamase and lactose promoter systems, alkaline phosphatase promoters, tryptophan (trp) promoter systems, and hybrid promoters (such as the tac promoter). However, other known bacterial promoters are also suitable. Promoters for bacterial systems also contain a Shine-Dalgarno (SD) sequence operably linked to the DNA encoding the antibody.

[0445] Transcription of the polypeptides from the vector in mammalian host cells is controlled, for example, by promoters obtained from the genome of viruses such as polyoma virus, fowlpox virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, most preferably Simian virus 40 (SV40), from heterologous mammalian promoters (e.g., the actin promoter or the immunoglobulin promoter), from heat shock promoters, provided that these promoters are compatible with the host cell systems.

[0446] The early and late promoters of the SV40 virus are conveniently obtained as SV40 restriction fragments, which also contain the SV40 viral replication origin. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. US 4,419,446 discloses a system for expressing DNA in a mammalian host using bovine papilloma virus as a vector. An improvement of this system is described in US 4,601,978. See also Reyes et al., Nature, Vol. 297: pp. 598-601 (1982) for the expression of human interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the Rous sarcoma virus long terminal repeat sequence can be used as a promoter.

[0447] e) Enhancer element components

[0448] Transcription of the DNA encoding the antibodies of the present disclosure by higher eukaryotes is usually increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known to come from mammalian genes (globulin, elastase, albumin, alpha-fetoprotein, and insulin). However, enhancers from eukaryotic cells are commonly used. Examples include the SV40 enhancer at the late stage of the replication origin (100-270 bp), the cytomegalovirus early promoter enhancer, the polyoma enhancer at the late stage of the replication origin, and adenovirus enhancers. The enhancer can be spliced ​​into the 5' or 3' position of the polypeptide coding sequence in the vector, but is preferably located at the 5' site of the promoter.

[0449] f) Transcription termination component

[0450] Expression vectors for eukaryotic host cells (yeast, fungi, insects, plants, animals, humans, or nucleated cells from other multicellular organisms) also contain sequences necessary for terminating transcription and stabilizing mRNA. Such sequences are usually available from the 5' untranslated region of eukaryotic or viral DNA or cDNA and occasionally from the 3' untranslated region of eukaryotic or viral DNA or cDNA. These regions contain nucleotide segments that are transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the polypeptide. A useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94 / 11026 and the expression vectors disclosed therein.

[0451] g) Host cell selection and transformation

[0452] Suitable host cells for cloning or expressing the DNA in the vectors herein include higher eukaryotic cells described herein, including vertebrate host cells. Propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are SV40-transformed monkey kidney CV1 line (COS-7, ATCC CRL 1651); human embryonic kidney cell line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., Vol. 36: 59-74 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells / -DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA, Vol. 77: 4216-4620 (1980)); mouse testicular Sertoli cells (TM4, Mather, Biol. Reprod., Vol. 23: 243-252 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical cancer cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatocytes (Hep G2, HB 8065); mouse mammary tumor (MMT060562, ATCC CCL51); TR1 cells (Mather et al., Ann. NY Acad. Sci., Vol. 383: 44-68 (1982)); MRC 5 cells; FS4 cells; and human hepatoma cell line (Hep G2).

[0453] Host cells are transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as necessary for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

[0454] h) Cultivating host cells

[0455] Host cells for producing antibodies of the present disclosure can be cultured in a variety of culture media. Commercially available culture media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma) and Dulbecco's Modified Eagle Medium ((DMEM), Sigma) are suitable for culturing host cells. The culture media may be supplemented with hormones and / or other growth factors (such as insulin, transferrin or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN TM Drugs), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art. The culture conditions (such as temperature and pH) are those previously used for the host cell selected for expression and are apparent to the ordinarily skilled artisan.

[0456] i) Protein purification

[0457] When recombinant techniques are used, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the culture medium. If the antibody is produced intracellularly, as a first step, the particulate debris (host cell or cleaved fragments) is removed, for example, by centrifugation or ultrafiltration. Carter et al., Biotechnology (NY), Vol. 10: pp. 163-167 (1992) describe a method for isolating antibodies secreted into the periplasmic space of E. coli. Briefly, the cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonyl fluoride (PMSF) for about 30 minutes. Cell debris can be removed by centrifugation. When the antibody is secreted into the culture medium, the supernatant from such an expression system is usually first concentrated using a commercially available protein concentration filter (e.g., Amicon or Millipore Pellicon ultrafiltration unit). Protease inhibitors (such as PMSF) may be included in any of the above steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of foreign contaminants.

[0458] Protein compositions prepared from cells can be purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the type and isotype of any immunoglobulin Fc domain present in the antibody. Protein A can be used to purify antibodies based on human immunoglobulins containing 1, 2, or 4 heavy chains. Protein G is recommended for all mouse isotypes and human 3. The matrix to which the affinity ligand is attached is most commonly agarose, but other matrices can also be used. Mechanically stable matrices such as controlled pore glass or poly(styrene-divinyl)benzene can achieve faster flow rates and shorter processing times than agarose. When the antibody contains C H 3 domains, Bayerbond ABX TM Resins (JT Baker, Phillipsburg, NJ) can be used for purification. Depending on the antibody to be recovered, other protein purification techniques may also be used, such as ion exchange column fractionation, ethanol precipitation, reverse phase HPLC, silica chromatography, anion or cation exchange resins (such as polyaspartic acid columns), heparin SEPHAROSE TM Chromatography, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation.

[0459] Following any preliminary purification steps, low pH hydrophobic interaction chromatography of a mixture containing the antibody of interest and contaminants may be performed using an elution buffer having a pH of about 2.5-4.5, preferably at low salt concentration (e.g., about 0-0.25 M salt).

[0460] 3. Polyclonal Antibodies

[0461] Polyclonal antibodies are usually raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. Bifunctional or derivatized agents such as maleimidobenzoyl sulfosuccinimide ester (conjugated through cysteine ​​residues), N-hydroxysuccinimide (conjugated through lysine residues), glutaraldehyde, succinic anhydride, SOCl2 or R 1 N=C=NR (where R and R 1 It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, such as keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Examples of adjuvants that can be used include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl lipid A, synthetic trehalose dipyrrolidone). The immunization protocol can be selected by those skilled in the art without undue experimentation.

[0462] Animals are immunized against antigens, immunogenic conjugates or derivatives by combining, for example, 100 μg or 5 μg of protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1 / 5 to 1 / 10 of the initial amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to fourteen days later, the animals are bled and the antibody titer of the serum is determined. The animals are boosted until the titer reaches a plateau. Conjugates can also be prepared as protein fusions in recombinant cell cultures. In addition, aggregating agents such as alum are suitable for enhancing immune responses. See also Example 1 for camel immunization.

[0463] 4. Monoclonal Antibodies

[0464] Monoclonal antibodies are obtained from a substantially homologous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts. Thus, the modifier "monoclonal" indicates that the characteristic of the antibody is not a mixture of discrete antibodies. For example, monoclonal antibodies may be prepared using the hybridoma method first described by Kohler et al., Nature, Vol. 256: pp. 495-497 (1975) or by recombinant DNA antibody methods (US 4,816,567). In the hybridoma method, mice or other suitable host animals (such as hamsters or llamas) are immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to proteins used for immunization. Alternatively, lymphocytes may be immunized in vitro. The lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). See also Example 1 for camel immunization.

[0465] The immunizing agent will generally include an antigenic protein or a fusion variant thereof. Typically, if human cells are desired, peripheral blood lymphocytes ("PBL") are used, or if non-human mammalian cells are desired, spleen cells or lymph node cells are used. The lymphocytes are then fused with an immortal cell line using a suitable fusing agent (such as polyethylene glycol) to form a hybridoma cell. Goding, Monoclonal Antibodies: Principles and Practice, Academic Press (1986), pp. 59-103.

[0466] Immortal cell lines are usually transformed mammalian cells, particularly myeloma cells from rodent, cattle and people.Usually, rat or mouse myeloma cell lines are used.The hybridoma cells thus prepared are inoculated in a suitable culture medium and grown therein, and the culture medium preferably contains one or more substances that suppress the growth or survival of the unfused parental myeloma cells.For example, if the parental myeloma cells lack hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium used for hybridomas will usually include hypoxanthine, aminopterin and thymidine (HAT culture medium), and these substances prevent the growth of HGPRT defective cells.

[0467] Preferred immortal myeloma cells are those that fuse efficiently, support stable high-level production of antibodies by selected antibody-producing cells, and are sensitive to a culture medium such as HAT medium. Among them, preferred are mouse myeloma cell lines, such as cell lines derived from MOPC-21 and MPC-11 mouse tumors obtained from the Salk Institute Cell Distribution Center in San Diego, California, USA, and SP-2 cells (and derivatives thereof, such as X63-Ag8-653) obtained from the American Type Culture Collection in Manassas, Virginia, USA.

[0468] Culture medium in which hybridoma cells are grown is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

[0469] The culture medium in which the hybridoma cells are cultured can be assayed for the presence of monoclonal antibodies directed against the desired antigen. Preferably, the binding affinity and specificity of the monoclonal antibodies can be determined by immunoprecipitation or by an in vitro binding assay such as a radioimmunoassay (RIA) or an enzyme-linked immunosorbent assay (ELISA). These techniques and assays are known in the art. For example, binding affinity can be determined by Scatchard analysis of Munson et al., Anal. Biochem., Vol. 107: pp. 220-239 (1980).

[0470] After identifying hybridoma cells that produce antibodies with the desired specificity, affinity and / or activity, the clones can be subcloned by limiting dilution methods and cultured by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 culture media. In addition, hybridoma cells can be grown as tumors in mammals.

[0471] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures (eg, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography).

[0472] Monoclonal antibodies can also be prepared by recombinant DNA methods. The DNA encoding the monoclonal antibody is easy to separate and sequenced using conventional methods (e.g., by using oligonucleotide probes that can bind to the genes encoding the heavy and light chains of mouse antibodies). Hybridoma cells are the preferred source of such DNA. Once the DNA is separated, it can be placed in an expression vector, which is then transfected into a host cell (such as an E. coli cell, ape COS cell, Chinese hamster ovary (CHO) cell or myeloma cell) that does not produce immunoglobulin in addition, so as to synthesize monoclonal antibodies in such recombinant host cells.

[0473] In another embodiment, antibodies can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, Vol. 348: 552-554 (1990). Clackson et al., Nature, Vol. 352: 624-628 (1991) and Marks et al., J. Mol. Biol., Vol. 222: 581-597 (1991) describe the use of antibody phage libraries to isolate mouse and human antibodies, respectively. Subsequent publications described the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., Biotechnology (NY), Vol. 10: pp. 779-783 (1992), and combined infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nucl. Acids Res., Vol. 21: pp. 2265-2266 (1993)). Therefore, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolating monoclonal antibodies.

[0474] DNA can also be modified, for example, by replacing the homologous mouse sequences with the coding sequences of human heavy and light chain constant regions (US 4,816,567; Morrison et al., Proc. Natl Acad. Sci., USA, Vol. 81: pp. 6851-6855 (1984)), or by covalently linking all or part of the coding sequence of a non-immunoglobulin polypeptide to the immunoglobulin coding sequence. Typically, such non-immunoglobulin polypeptides replace the constant domains of an antibody, or replace the variable domains of one antigen-binding site of an antibody to produce a chimeric bivalent antibody comprising one antigen-binding site specific for an antigen and another antigen-binding site specific for another antigen.

[0475] The monoclonal antibodies described herein can be monovalent, and their preparation methods are well known in the art. For example, one method includes recombinant expression of immunoglobulin light chains and modified heavy chains. The heavy chain is usually truncated at any site in the Fc region to prevent heavy chain cross-linking. Alternatively, the relevant cysteine ​​residues can be replaced or deleted by another amino acid residue to prevent cross-linking. In vitro methods are also suitable for preparing monovalent antibodies. Conventional techniques known in the art can be used to digest antibodies to produce fragments thereof, particularly Fab fragments.

[0476] Chimeric or hybrid antibodies can also be prepared in vitro using methods known in synthetic protein chemistry, including methods involving cross-linking agents. For example, immunotoxins can be constructed using disulfide exchange reactions or by forming thioether bonds. Examples of reagents suitable for this purpose include iminothiol esters and methyl-4-mercaptobutyrimide esters.

[0477] See also Example 1 regarding the production of monoclonal sdAbs.

[0478] 5. Humanized Antibodies

[0479] The humanized form of non-human (e.g., mouse) antibodies is a chimeric immunoglobulin, immunoglobulin chain, or fragment thereof (such as an antibody's Fv, Fab', F(ab')2, or other antigen-binding subsequence) containing minimal sequences derived from non-human immunoglobulins. Humanized antibodies include human immunoglobulins (receptor antibodies), wherein residues from receptor CDRs are replaced by residues from non-human species (donor antibodies) CDRs, such as mice, rats, rabbits, camelids, or llamas, and the CDRs of these species have the desired specificity, affinity, and binding capacity. In some cases, the Fv framework residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also include residues that are neither present in the receptor antibody nor in the CDR or framework sequences that are introduced. Typically, humanized antibodies may include substantially all of at least one, usually two variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins, and all or substantially all of the FR regions are FR regions of human immunoglobulin consensus sequences. In certain embodiments, a humanized antibody will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See Jones et al., Nature, Vol. 321: 522-525 (1986); Riechmann et al., Nature, Vol. 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., Vol. 2: 593-596 (1992).

[0480] Methods for humanizing non-human antibodies are well known in the art. Typically, humanized antibodies have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "imported" residues, which are usually taken from the "imported" variable domain. Humanization can be performed essentially according to the methods of Winter and colleagues, Jones et al., Nature, Vol. 321: pp. 522-525 (1986); Riechmann et al., Nature, Vol. 332: pp. 323-327 (1988); Verhoeyen et al., Science, Vol. 239: pp. 1534-1536 (1988), and can also be performed by replacing the corresponding sequence of a human antibody with a rodent CDR or CDR sequence. Therefore, such "humanized" antibodies are chimeric antibodies (US 4,816,567), in which substantially less than the complete human variable domain is replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0481] The selection of human variable domains (light and heavy chains) for preparing humanized antibodies is very important for reducing antigenicity. According to the so-called "best fit" method, the variable domain sequences of rodent antibodies are screened for the entire library of known human variable domain sequences. The human sequence closest to the rodent sequence is then used as the human framework (FR) of the humanized antibody. Sims et al., J.Immunol., Vol. 151: pp. 2296-2308 (1993); Chothia et al., J.Mol.Biol., Vol. 196: pp. 901-917 (1987). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a specific subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies.

[0482] More importantly, the high affinity to antigen and other favorable biological properties are retained while the antibody is humanized. In order to achieve this goal, according to a preferred method, humanized antibodies are prepared by using the three-dimensional model analysis of the parental sequence and various conceptual humanized products of the parental and humanized sequences. The three-dimensional immunoglobulin model is usually available and familiar to those skilled in the art. The computer program of the possible three-dimensional conformational structure of the candidate immunoglobulin sequence selected can be obtained to illustrate and display. The inspection of these displays allows the analysis of the possible effects of residues in the function of the candidate immunoglobulin sequence, i.e., the residues that affect the ability of the candidate immunoglobulin to bind its antigen. By this method, FR residues can be selected and combined from receptors and imported sequences to obtain required antibody characteristics, such as increased affinity to the target antigen. Usually, CDR residues directly and most substantially participate in affecting antigen binding.

[0483] In certain embodiments, a sdAb is modified, such as a humanized sdAb, without reducing the natural affinity of the domain for the antigen while reducing the immunogenicity of the sdAb to a heterologous species. For example, the antibody variable domain (V H In some embodiments, the humanization of camelid sdAbs is carried out by replacing the amino acid residues of the human H) in the framework region, and one or more camelid amino acids in the framework region are replaced by their human counterparts present in the human consensus sequence, without the polypeptide losing its typical characteristics, i.e., the humanization does not significantly affect the antigen binding ability of the resulting polypeptide. The humanization of camelid sdAbs requires the introduction and mutagenesis of a limited number of amino acids in a single polypeptide chain. This is in contrast to the humanization of scFv, Fab', (Fab')2 and IgG, which requires the introduction of amino acid changes in two chains (light chain and heavy chain) and the maintenance of the assembly of these two chains.

[0484] 6. Human Antibodies

[0485] As an alternative to humanization, human antibodies can be produced. For example, it is now possible to produce transgenic animals (e.g., mice) that are able to produce a complete human antibody repertoire after immunization without producing endogenous immunoglobulins. For example, chimeric and germline mutant mice have been described for the antibody heavy chain joining region (J-J) H Homozygous deletion of the ) gene results in complete inhibition of endogenous antibody production. Transfer of the human germline immunoglobulin gene array into such germline mutant mice results in the production of human antibodies upon antigen challenge.

[0486] Alternatively, phage display technology can be used to produce human antibodies and antibody fragments in vitro from immunoglobulin variable (V) domain gene libraries from unimmunized donors. McCafferty et al., Nature, Vol. 348: pp. 552-553 (1990); Hoogenboom and Winter, J. Mol. Biol. Vol. 227: pp. 381-388 (1992). According to this technology, the antibody V domain gene is cloned into the major or minor coat protein gene of a filamentous phage (such as M13 or fd) in the correct frame and displayed as a functional antibody fragment on the surface of the phage particle. Because the filamentous particles contain a single-stranded DNA copy of the phage genome, selection based on the functional properties of the antibody also leads to selection of genes encoding antibodies that exhibit these properties. Therefore, phages mimic some characteristics of B cells. Phage display can be performed in a variety of forms. V gene segments from several sources can be used for phage display. Clackson et al., Nature, Vol. 352: 624-628 (1991). V gene repertoires from unimmunized human donors can be constructed essentially according to the techniques described in Marks et al., J. Mol. Biol., Vol. 222: 581-597 (1991) or Griffith et al., EMBO J., Vol. 12: 725-734 (1993), and antibodies against a diverse array of antigens (including self-antigens) can be isolated. See also US 5,565,332 and US 5,573,905.

[0487] The techniques of Cole et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985)) and Boerner et al. (J. Immunol., Vol. 147: pp. 86-95 (1991)) can also be used to prepare human monoclonal antibodies. Similarly, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals, such as mice in which endogenous immunoglobulin genes have been partially or completely inactivated. After challenge, human antibody production was observed to be very similar to human antibody production in all aspects, including gene rearrangement, assembly, and antibody repertoire. This method is described in, for example, US 5,545,807; US 5,545,806; US 5,569,825; US 5,625,126; US 5,633,425; and US 5,661,016; and Marks et al., Biotechnology (NY), Vol. 10: pp. 779-783 (1992); Lonberg et al., Nature, Vol. 368: pp. 856-859 (1994); Morrison, Nature, Vol. 368: pp. 812-813 (1994); Fishwild et al., Nat. Biotechnol., Vol. 14: pp. 845-851 (1996); Neuberger, Nat. Biotechnol., Vol. 14: pp. 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol., Vol. 13: pp. 65-93 (1995). For example, in certain embodiments, human antibodies (e.g., human DAbs) can be produced by immunizing human HCAb mice. For example, HCAbs (eg, sdAb-Fc fusion proteins) can be produced by immunizing transgenic mice in which endogenous murine antibody expression has been eliminated and a human transgene has been introduced. HCAb mice are disclosed in US 8,883,150; US 8,921,524; US 8,921,522; US 8,507,748; US 8,502,014; US 2014 / 0356908; US 2014 / 0033335; US 2014 / 0037616; US 2014 / 0356908; US 2013 / 0344057; US 2013 / 0323235; US 2011 / 0118444; and US 2009 / 0307787; all of which disclose heavy chain antibodies and their production in transgenic mice, and are all incorporated herein by reference. HCAb mice are immunized, and the resulting sensitized spleen cells are fused with murine myeloma cells to form hybridomas.The resulting HCAb can then be fully humanized by replacing the murine CH2 and CH3 regions with human sequences.

[0488] Finally, human antibodies can also be produced by in vitro activated B cells (see US 5,567,610 and US 5,229,275) or by using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., Vol. 227: 381-388 (1992); Marks et al., J. Mol. Biol., Vol. 222: 581-597 (1991)).

[0489] VII. Products and Kits

[0490] In certain embodiments, an article containing materials for treating a disease or condition in an individual is provided for administering an anti-albumin construct to the individual. The article may include a container and a label or package insert associated with the container or the container. Suitable containers include, for example, bottles, vials, and syringes. The container may be formed of a variety of materials, such as glass or plastic. Typically, the container holds a composition effective for treating a disease or condition as described herein and may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a stopper pierced by a hypodermic needle). At least one active agent in the composition is an anti-albumin construct as described herein. The label or package insert indicates that the composition is used to treat a specific condition. The label or package insert also includes instructions for administering the anti-albumin construct to a patient. Articles and kits including the combination therapies described herein are also contemplated.

[0491] Package insert refers to instructions customarily included in commercial packages of therapeutic products, which contain information about the indications, usage, dosage, administration, contraindications, and / or warnings concerning the use of such therapeutic products. In certain embodiments, the package insert indicates that the composition is used to treat a disease or disorder (such as cancer or inflammatory disease).

[0492] In addition, the article of manufacture may further include a second container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. The article of manufacture may also include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0493] Also provided are kits for various purposes, e.g., for treating a disease or condition described herein (such as cancer or inflammatory disease), for administering an anti-albumin construct to an individual, optionally in combination with an article. The kit of the present disclosure includes one or more containers containing an anti-albumin construct composition (or unit dosage form and / or article), and in certain embodiments, also includes another medicament (such as a medicament described herein) and / or instructions for use according to any method described herein. The kit may also include a description of selecting an individual suitable for treatment. The instructions provided in the kit of the present disclosure are typically written instructions on a label or package insert (e.g., a sheet of paper included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.

[0494] For example, in certain embodiments, the kit includes a composition containing an anti-albumin construct. In certain embodiments, the kit includes a) a composition containing an anti-albumin construct, and b) an effective amount of at least one other agent as described herein. In certain embodiments, the kit includes a) a composition containing an anti-albumin construct, and b) instructions for applying the anti-albumin construct composition to an individual for treatment. In certain embodiments, the kit includes a) a composition containing an anti-albumin construct, b) an effective amount of at least one other agent as described herein, and c) instructions for applying the anti-albumin construct composition and other agents to an individual for treatment. The anti-albumin construct and other agents may be present in separate containers or in a single container. For example, the kit may include a specific composition or two or more compositions, wherein one composition includes an anti-albumin construct and another composition includes another agent.

[0495] The kit of the present invention has suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, and flexible packaging (e.g., sealed Mylar or plastic bags). The kit may optionally provide additional components, such as buffer and explanatory information. Therefore, the present disclosure also provides articles, which include vials (such as sealed vials), bottles, jars, and flexible packaging.

[0496] Instructions related to the use of anti-albumin construct compositions typically include information about dosage, dosing regimen, and route of administration for the intended treatment. The container may be a unit dose, bulk package (e.g., multi-dose package), or subunit dose. For example, a kit containing a sufficient dose of an anti-albumin construct as disclosed herein may be provided to provide long-term effective treatment for an individual, such as one week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or any one of longer periods. The kit may also include multiple unit doses of anti-albumin constructs and pharmaceutical compositions and instructions for use, and packaged in an amount sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and a compounding pharmacy).

[0497] Those skilled in the art will recognize that within the scope and spirit of the present disclosure, several embodiments are possible. The present disclosure is now described in more detail with reference to the following non-limiting examples. The following examples further illustrate the present disclosure, but of course should not be construed as limiting its scope in any way.

[0498] Example

[0499] The following examples are intended to be illustrative of the present disclosure and therefore should not be considered to limit the scope of the present disclosure in any way.

[0500] Example 1. Generation of anti-HSA single domain antibodies

[0501] Llamas were immunized with human serum albumin (HSA) expressed in mice (Sigma, #A9731) to produce anti-HSA single domain antibodies (V H H antibody). After immunization, peripheral mononuclear cells (PBMC) were isolated for RNA extraction. V H H antibody phage display library. The constructed phage display library was screened by multiple rounds of affinity binding with antigens. Affinity measurement ( RED96) to identify positive clones. The antibody genes of positive clones were sequenced and cloned into vector (EMD Millipore, #CS221284) for Chinese hamster ovary (CHO) cell expression.

[0502] Table 4 lists exemplary anti-HSA single domains (e.g., V H H) antibodies (e.g., antibodies A1 to A18). These exemplary V HThe CDR sequences of the H antibodies are listed in Table 5. Among these antibodies, antibody A8 interacted with human, cynomolgus monkey and mouse serum albumin. Antibodies A1 to A7 and A9 interacted with human and cynomolgus monkey serum albumin.

[0503] Table 4. Anti-HSA V H Amino acid sequence of H antibody

[0504]

[0505]

[0506]

[0507] Table 5. Anti-HSA V H CDR sequences of H antibody

[0508]

[0509] Example 2. Generation of humanized anti-HSA single domain antibodies

[0510] Each llama sequence of an anti-HSA single domain antibody (sdAb) was directed against The best matching human IGHV3 germline was identified by comparing the germline with the corresponding human IGHV3 database. The similarity of the amino acid at position 52 of FR2 in the numbering system determines which germline to use as the humanized scaffold. FR1 and FR3 from the selected germline are then used as "humanized" FR1 and FR3. For FR2, most of the human sequence is used except for positions 42 and 52, at which the respective llama sequences are retained. Table 6 shows exemplary human FR region sequences for each of the anti-HSA antibodies. For human FR4, humanized antibodies A1-A9, A19 and A20 each independently have an amino acid sequence of WGQGTQVTVSS (SEQ ID NO: 145), WGQGTLVTVSS (SEQ ID NO: 146) or SGQGTQVTVSS (SEQ ID NO: 147). In one embodiment, for human FR4, humanized antibodies A1-A9 each have an amino acid sequence of WGQGTQVTVSS (SEQ ID NO: 145). In another embodiment, for human FR4, humanized antibody A19 has an amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 146). In another embodiment, for human FR4, humanized antibody A19 has an amino acid sequence of SGQGTQVTVSS (SEQ ID NO: 147).

[0511] Table 6. Humanized anti-HSA VH H antibody framework region

[0512]

[0513]

[0514] Example 3. Binding dissociation constant (K) of anti-albumin antibodies D )

[0515] Rating V H The ability of the H anti-albumin antibody to interact with human, monkey and mouse serum albumin at different pH values ​​(e.g., pH 7.4 or pH 5.5) to mimic the pH of acidified endosomes. H H anti-albumin antibody was fused to human IgG1-Fc. The expressed protein was then loaded onto the protein A biosensor ( The biosensor was then immersed in a solution containing three or more different concentrations of human, monkey or mouse serum, such as 50 nM, 100 nM or 200 nM, or 100 nM, 200 nM or 400 nM. The primary experimental data were analyzed using global fitting to determine the binding dissociation constant (K D The results are summarized in Table 7 (pH 5.5) and Table 8 (pH 7.4), where A represents a value not greater than 10 nM, B represents a value greater than 10 nM but not greater than 100 nM, and C represents a value greater than 100 nM but not greater than 500 nM.

[0516] Table 7. Binding dissociation constants (K) of anti-albumin antibodies to human and monkey serum albumin at pH 5.5 D )

[0517] Ab No. people monkey A8 A B A10 B B A20 B B

[0518] Table 8. Binding dissociation constants (K) of anti-albumin antibodies to human, monkey and mouse serum albumin at pH 7.4 D )

[0519]

[0520]

[0521] NA—No binding detected

[0522] The results in Table 8 show that antibody A19, a humanized anti-albumin antibody of antibody A8, retains its binding to human, monkey and mouse serum albumin. The results in Tables 7 and 8 also show that the anti-albumin antibodies retain their binding to human and monkey serum albumin at low pH, indicating that such antibodies are suitable for acidic environments (e.g., acidified endosomes).

[0523] Example 4. Molecular cloning of IL-21 anti-HSA constructs

[0524] The construction of the IL-21 anti-HSA construct expression vector is exemplified herein. cDNA sequences encoding full-length human IL-21 (SEQ ID NO: 97) were obtained by gene synthesis (ThermoFisher Scientific). Codon usage of these genes was optimized for expression in Chinese hamster ovary (CHO) cells. The C-terminus of human IL-21 was ligated to anti-HSA V via a peptide linker. H The peptide linker and anti-HSA V were fused to the N-terminus of the H antibody. H The DNA sequence of the H antibody was seamlessly assembled. The oligonucleotides of the IL-21-anti-HSA fusion protein were inserted The expression vector CET1019-AS-Puro (EMD Millipore, #CS221284) was used for CHO cell expression. Table 9 lists the sequence of human IL-21. Table 10 lists exemplary peptide linkers suitable for IL-21-anti-HSA constructs.

[0525] Table 9. Interleukin-21 (IL-21)

[0526]

[0527]

[0528] Table 10. Peptide linkers

[0529]

[0530] Example 5. Expression and purification of IL-21-anti-albumin constructs

[0531] The DNA sequence encoding the IL-21 anti-albumin construct was found in EXPICHO-S TM Cells (GIBCO TM , #A29127) for transient expression. TM 3×10 6 cells / mL-4×10 6 The cells were inoculated at a density of 10 cells / mL in an Erlenmeyer shake flask with aeration. TMExpression medium (GIBCO, #A2910001) and placed on an orbital shaker at 125 rpm in a 37°C incubator with 8% CO2. On day 0, plasmid DNA was mixed with EXPIFECTAMINE TM CHO reagent. Then slowly add the mixture to the cells. After 16 hours, transfer the cells to a 32°C incubator with 5% CO2. Add EXPICHO to the cells on days 1 and 5. TM Culture medium (GIBCO TM , #A29129) twice. CHO cells were harvested on days 8-12 for purification by affinity column.

[0532] Example 6. IL-21-anti-HSA construct: IL-21 signaling potency similar to recombinant human IL-21

[0533] Pfeiffer cells were maintained in RPMI-1640 containing 10% fetal bovine serum and penicillin / streptomycin. Pfeiffer cells (100,000) were treated with the indicated concentrations of recombinant human IL-21 (rhIL-21) (SEQ ID NO: 97), mouse IL-21-anti-HSA construct C1 (SEQ ID NO: 99), or human IL-21-anti-HSA construct C2 (SEQ ID NO: 100) in Hanks balanced salt solution containing 10 mM HEPES at 37° C., 5% CO 2 for 30 minutes. Phospho-STAT3 was measured using the phospho-STAT3 (Tyr705) homogeneous time-resolved fluorescence (HTRF) assay (Cisbio) according to the manufacturer's instructions. The signal ratio at 665 nm / 620 nm was multiplied by 1,000, plotted, and a dose response curve fit (Graphpad Prism) was used to calculate the EC 50. The results are summarized in Table 11, indicating that IL-21 anti-HSA constructs C1 and C2 and recombinant hIL-21 have similar potency. In Table 11, construct C1 is a mouse IL-21-anti-HSA fusion protein comprising a mouse IL-21 (mIL-21) portion of SEQ ID NO: 148, an anti-HSA antibody portion of SEQ ID NO: 8, and a peptide linker of (GSG) 4 (SEQ ID NO: 58); wherein the C-terminus of the mIL-21 is connected to the N-terminus of the anti-HSA antibody via the peptide linker. Construct C2 (SEQ ID NO: 100) is a human IL-21-anti-HSA fusion protein comprising a human IL-21 (hIL-21) portion of SEQ ID NO: 97, an anti-HSA antibody portion of SEQ ID NO: 8, and a peptide linker of (GSG) 4 (SEQ ID NO: 58); wherein the C-terminus of the hIL-21 is connected to the N-terminus of the anti-HSA antibody via the peptide linker.

[0534] Table 11. EC of different IL-21 variants 50

[0535]

[0536] Example 7. ADCC activity

[0537] NCI-N87 and NCI-H226 cancer cell lines were maintained in RPMI-1640 containing 10% fetal bovine serum and penicillin / streptomycin. On day 0, NCI-N87 cells (10,000 per well) and NCI-H226 cells (5,000 per well) were plated in culture medium in 96-well flat-bottom plates. On day 1, ROSETTESEP TM NK cells were isolated from human buffy coat using the NK Isolation Kit (Stemcell Technologies). NK cells (100,000 per well) were then added to the cancer cells along with the indicated treatments.

[0538] After NCI-N87 and NCH-H226 cells were cultured at 37°C and 5% CO2 for 24 or 48 hours, they were fixed with 4% paraformaldehyde and stained with SYTOX TM Orange stains the cell nucleus. TM 1 (Biotek) count the number of remaining cancer cell nuclei in each well to calculate the number of remaining cancer cells. The lower the cell count, the better the NK-mediated cell killing.

[0539] like Figure 1 and Figure 2As shown, when combined with anti-MSLN B1, mIL-21-anti-HSA construct C1 (SEQ ID NO: 99) and hIL-21-anti-HSA construct C2 (SEQ ID NO: 100) enhanced NK cell ADCC activity. The extent of ADCC enhancement by IL-21 anti-HSA constructs C1 and C2 was similar to that of rhIL-21. Figure 1 and Figure 2 In the construct, anti-MSLN B1, a single domain anti-MSLN antibody, comprises CDR1 of SEQ ID NO: 92, CDR2 of SEQ ID NO: 93, and CDR3 of SEQ ID NO: 94. C5 represents human IL-15 of SEQ ID NO: 102. Construct C6 (SEQ ID NO: 103) represents an IL-15Rα-anti-HSA construct comprising a fragment of human IL-15Rα (hIL-15Rα) (SEQ ID NO: 102) and an anti-HSA antibody portion of SEQ ID NO: 8 and a peptide linker of (G4S)4 (SEQ ID NO: 60).

[0540] like Figure 3 and Figure 4 As shown, when combined with anti-MSLN B1, IL-21-anti-HSA constructs (i) C1, (ii) C2, (iii) rhIL-15C5 / hIL-15Rα-anti-HSA construct C6 combination, and (iv) rhIL-15C5 / hIL-15Rα-anti-HSA construct C7 combination showed full ADCC efficacy, which could be reduced to 0.6 ng / mL or lower. Construct C7 (SEQ ID NO: 104) represents an IL-15Rα-anti-HSA construct comprising a fragment of human IL-15Rα and an anti-HSA antibody portion of SEQ ID NO: 8 and a peptide linker of (G4S)4 (SEQ ID NO: 60).

[0541] Example 8. In vivo antitumor activity in a syngeneic mouse model

[0542] On day 0, MC38 mouse colon cancer cells (3×10 6 Cells) were subcutaneously implanted into the flank of C57BL / 6 mice. On days 4, 8, 12, and 16, mice were treated with PBS, anti-mPD-1 (100 μg), mIL-21-anti-HSA construct C1 (25 μg), anti-mPD-1 (100 μg) and mIL-21-anti-HSA construct C1 (25 μg), or anti-mPD-1 (100 μg) and mIL-21-anti-HSA construct C1 (5 μg). Tumor size was measured using a caliper on the designated days, and tumor volume was then calculated.

[0543] like Figure 5 As shown, monotherapy with mIL-21-anti-HSA construct C1 significantly slowed tumor growth. The combination of mIL-21-anti-HSA construct C1 and anti-mPD-1 eliminated or shrank tumors in all mice.

[0544] Example 9. Mouse PK Study of hIL-21-Anti-HSA Construct C2

[0545] At time 0, Balb / c mice were injected intraperitoneally with hIL-21-anti-HSA construct C2. At the indicated time points, blood (100 μL) was collected from the saphenous vein. The blood was placed in EDTA blood collection tubes, placed on ice, and centrifuged. The plasma was then transferred to a 1.5 mL tube, frozen and stored at -80°C. To measure hIL-21 concentrations, plasma samples were thawed and tested using human IL-21 ELISA (Invitrogen) according to the manufacturer's instructions. Figure 6 As shown, based on the in vitro dose response data, effective IL-21 concentrations are believed to be maintained for at least 3-4 days. The PK parameters of hIL-21-anti-HSA construct C2 at 3 μg and 30 μg doses were determined and are summarized in Table 12.

[0546] Table 12. PK parameters of hIL-21-anti-HSA construct C2 in mice

[0547]

[0548]

[0549] Example 10. PK study of IL-21 anti-HSA construct in transgenic mice

[0550] hIL-21-anti-HSA construct C3 (SEQ ID NO: 149) (3 μg) or hIL-21-anti-HSA construct C4 (SEQ ID NO: 150) (3 μg) was administered to transgenic mice (Genoway) transgenically expressing human serum albumin and human neonatal Fc receptor and knocking out mouse albumin and mouse neonatal Fc receptor. After 1, 24, 48, 96, 168 and 336 hours, the blood of the mice was collected and processed into plasma using EDTA as an anticoagulant. The samples were analyzed for IL-21 concentration using a commercial ELISA kit (Thermo Fisher). The PK parameters of hIL-21-anti-HSA constructs C3 and C4 at a dose of 3 μg were determined and are summarized in Table 13. Compared with anti-HSA A19, when conjugated to anti-HSA A20, the C of IL-21 was significantly higher than that of anti-HSA A19. max and t 1 / 2 Bigger.

[0551] Table 13. PK parameters of IL-21 anti-HSA constructs C3 and C4 in transgenic mice

[0552]

[0553] The following sequence listing provides the sequences described herein.

[0554] Sequence Listing

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567] *****

[0568] The above examples are provided to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments, but not to limit the scope of what is disclosed herein. Modifications that are obvious to those skilled in the art should be within the scope of the appended claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference, as if each such publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference.

Claims

1. An isolated anti-albumin construct comprising a single domain antibody (sdAb) portion, the sdAb portion comprising: (1) CDR1 of the amino acid sequence of SEQ ID NO: 10; CDR2 of the amino acid sequence of SEQ ID NO: 11; as well as CDR3 of the amino acid sequence of SEQ ID NO: 12; (2) CDR1 of the amino acid sequence of SEQ ID NO: 13; CDR2 of the amino acid sequence of SEQ ID NO: 14; and CDR3 of the amino acid sequence of SEQ ID NO: 15; (3) CDR1 of the amino acid sequence of SEQ ID NO: 16; CDR2 of the amino acid sequence of SEQ ID NO: 17; and CDR3 of the amino acid sequence of SEQ ID NO: 18; (4) CDR1 of the amino acid sequence of SEQ ID NO: 19; CDR2 of the amino acid sequence of SEQ ID NO:20; and CDR3 of the amino acid sequence of SEQ ID NO:21; (5) CDR1 of the amino acid sequence of SEQ ID NO:22; CDR2 of the amino acid sequence of SEQ ID NO:23; and CDR3 of the amino acid sequence of SEQ ID NO:24; (6) CDR1 of the amino acid sequence of SEQ ID NO:25; CDR2 of the amino acid sequence of SEQ ID NO:26; and CDR3 of the amino acid sequence of SEQ ID NO:27; (7) CDR1 of the amino acid sequence of SEQ ID NO:28; CDR2 of the amino acid sequence of SEQ ID NO:29; and CDR3 of the amino acid sequence of SEQ ID NO:30; (8) CDR1 of the amino acid sequence of SEQ ID NO:31; CDR2 of the amino acid sequence of SEQ ID NO:32; and CDR3 of the amino acid sequence of SEQ ID NO:33; (9) CDR1 of the amino acid sequence of SEQ ID NO:34; CDR2 of the amino acid sequence of SEQ ID NO:35; and CDR3 of the amino acid sequence of SEQ ID NO:36; (10) CDR1 of the amino acid sequence of SEQ ID NO: 116; CDR2 of the amino acid sequence of SEQ ID NO:35; and CDR3 of the amino acid sequence of SEQ ID NO:117; (11) CDR1 of the amino acid sequence of SEQ ID NO: 121; CDR2 of the amino acid sequence of SEQ ID NO: 122; and CDR3 of the amino acid sequence of SEQ ID NO:123; (12) CDR1 of the amino acid sequence of SEQ ID NO: 124; CDR2 of the amino acid sequence of SEQ ID NO: 125; and CDR3 of the amino acid sequence of SEQ ID NO:126; (13) CDR1 of the amino acid sequence of SEQ ID NO: 121; CDR2 of the amino acid sequence of SEQ ID NO: 127; and CDR3 of the amino acid sequence of SEQ ID NO:128; (14) CDR1 of the amino acid sequence of SEQ ID NO: 129; CDR2 of the amino acid sequence of SEQ ID NO: 130; and CDR3 of the amino acid sequence of SEQ ID NO: 131; (15) CDR1 of the amino acid sequence of SEQ ID NO: 132; CDR2 of the amino acid sequence of SEQ ID NO: 133; and CDR3 of the amino acid sequence of SEQ ID NO: 134; or (16) CDR1 of the amino acid sequence of SEQ ID NO: 135; CDR2 of the amino acid sequence of SEQ ID NO: 136; and CDR3 of the amino acid sequence of SEQ ID NO:

137.

2. The anti-albumin construct of claim 1, wherein the sdAb portion comprises: (1) CDR1 of the amino acid sequence of SEQ ID NO: 10; CDR2 of the amino acid sequence of SEQ ID NO: 11; as well as CDR3 of the amino acid sequence of SEQ ID NO: 12; (2) CDR1 of the amino acid sequence of SEQ ID NO: 13; CDR2 of the amino acid sequence of SEQ ID NO: 14; and CDR3 of the amino acid sequence of SEQ ID NO: 15; (3) CDR1 of the amino acid sequence of SEQ ID NO: 16; CDR2 of the amino acid sequence of SEQ ID NO: 17; and CDR3 of the amino acid sequence of SEQ ID NO: 18; (4) CDR1 of the amino acid sequence of SEQ ID NO: 19; CDR2 of the amino acid sequence of SEQ ID NO:20; and CDR3 of the amino acid sequence of SEQ ID NO:21; (5) CDR1 of the amino acid sequence of SEQ ID NO:22; CDR2 of the amino acid sequence of SEQ ID NO:23; and CDR3 of the amino acid sequence of SEQ ID NO:24; (6) CDR1 of the amino acid sequence of SEQ ID NO:25; CDR2 of the amino acid sequence of SEQ ID NO:26; and CDR3 of the amino acid sequence of SEQ ID NO:27; (7) CDR1 of the amino acid sequence of SEQ ID NO:28; CDR2 of the amino acid sequence of SEQ ID NO:29; and CDR3 of the amino acid sequence of SEQ ID NO:30; (8) CDR1 of the amino acid sequence of SEQ ID NO:31; CDR2 of the amino acid sequence of SEQ ID NO:32; and CDR3 of the amino acid sequence of SEQ ID NO:33; (9) CDR1 of the amino acid sequence of SEQ ID NO:34; CDR2 of the amino acid sequence of SEQ ID NO:35; and CDR3 of the amino acid sequence of SEQ ID NO:36; or (10) CDR1 of the amino acid sequence of SEQ ID NO:129; CDR2 of the amino acid sequence of SEQ ID NO: 130; and CDR3 of the amino acid sequence of SEQ ID NO:

131.

3. The anti-albumin construct of claim 2, wherein the sdAb portion comprises: (1) CDR1 of the amino acid sequence of SEQ ID NO:31; CDR2 of the amino acid sequence of SEQ ID NO:32; as well as CDR3 of the amino acid sequence of SEQ ID NO:33; (2) CDR1 of the amino acid sequence of SEQ ID NO:34; CDR2 of the amino acid sequence of SEQ ID NO:35; and CDR3 of the amino acid sequence of SEQ ID NO:36; or (3) CDR1 of the amino acid sequence of SEQ ID NO: 129; CDR2 of the amino acid sequence of SEQ ID NO: 130; and CDR3 of the amino acid sequence of SEQ ID NO:

131.

4. An anti-albumin construct according to any one of claims 1 to 3, wherein the sdAb portion is camelid, chimeric, human or humanized.

5. An anti-albumin construct according to claim 4, wherein the sdAb portion is humanized.

6. The anti-albumin construct according to claim 4 or 5, wherein the sdAb portion further comprises: FR1 having the amino acid sequence of SEQ ID NO:37, 38, 39 or 141; FR2 having the amino acid sequence of SEQ ID NO:40, 41, 42, 142 or 143; FR3 having the amino acid sequence of SEQ ID NO:43, 44 or 144; and / or FR4 having the amino acid sequence of SEQ ID NO:145, 146 or 147.

7. The anti-albumin construct according to any one of claims 1 to 6, wherein the sdAb portion comprises: A heavy chain variable domain having the amino acid sequence of any one of SEQ ID NOs: 1 to 9, 45 to 53, 99 to 101, 103 to 115, 149 and 150; or a variant thereof having at least about 80% sequence identity with any one of SEQ ID NOs: 1 to 9, 45 to 53, 99 to 101, 103 to 115, 149 and 150.

8. The anti-albumin construct according to any one of claims 1 to 7, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 1 to 9, 45 to 53, 114 and 115.

9. The anti-albumin construct according to any one of claims 1 to 8, wherein the sdAb portion comprises a heavy chain variable domain having an amino acid sequence of any one of SEQ ID NOs: 45 to 53, 114 and 115.

10. The anti-albumin construct according to any one of claims 1 to 9, wherein the sdAb portion comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 52, 114 or 115.

11. The anti-albumin construct according to any one of claims 1 to 10, wherein the albumin is human serum albumin, rhesus serum albumin, cynomolgus serum albumin and mouse serum albumin.

12. An anti-albumin construct according to any one of claims 1 to 11, wherein the albumin is human serum albumin.

13. The anti-albumin construct of claim 12, wherein the human serum albumin has the amino acid sequence of SEQ ID NO: 54, 55, 56 or 57.

14. The anti-albumin construct according to any one of claims 1 to 13, wherein the construct is soluble in water at a pH of about 10 -6 M to about 10 -10 M of K D Binds to the albumin.

15. The anti-albumin construct of any one of claims 1 to 14, wherein the construct is diluted to about 10 μg / ml at a pH of about 5.

5. -6 M to about 10 -10 M of K D Binds to the albumin.

16. An anti-albumin construct according to any one of claims 1 to 15, further comprising a second polypeptide portion.

17. An anti-albumin construct according to claim 16, wherein the C-terminus of the second polypeptide portion is fused to the N-terminus of the sdAb portion.

18. The anti-albumin construct of claim 16, wherein the N-terminus of the second polypeptide portion is fused to the C-terminus of the sdAb portion.

19. An anti-albumin construct according to any one of claims 16 to 18, wherein the second polypeptide portion is fused to the sdAb portion via a peptide linker.

20. The anti-albumin construct of claim 19, wherein the peptide linker is cleavable.

21. An anti-albumin construct according to claim 19 or 20, wherein the peptide linker comprises an amino acid sequence of any one of SEQ ID NOs: 73 to 91.

22. The anti-albumin construct of claim 19, wherein the peptide linker is non-cleavable.

23. An anti-albumin construct according to claim 19 or 22, wherein the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 58 to 72.

24. An anti-albumin construct according to any one of claims 16 to 23, wherein the second polypeptide portion comprises an antigen binding portion.

25. The anti-albumin construct of claim 24, wherein the anti-albumin construct binds to a tumor antigen via the antigen binding moiety.

26. The anti-albumin construct of claim 25, wherein the tumor antigen is mesothelin, GPA33, Her-2, EGFR or CD20.

27. An anti-albumin construct according to claim 25 or 26, wherein the tumor antigen is mesothelin.

28. An anti-albumin construct according to any one of claims 25 to 27, wherein the antigen binding portion comprises a single domain antibody portion comprising: A CDR1 comprising the amino acid sequence of SEQ ID NO: 92 or 95; a CDR2 comprising the amino acid sequence of SEQ ID NO: 93 or 96; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 94 or GRY.

29. The anti-albumin construct of claim 25, wherein the tumor antigen is CEA, MUC16, MUC1, AFP, EPCAM, CD19, CD21, CD22, CD30, CD33, CD37, CD45, PSMA or BCMA.

30. An anti-albumin construct according to any one of claims 16 to 23, wherein the second polypeptide portion comprises the amino acid sequence of a cytokine or a fragment thereof.

31. The anti-albumin construct of claim 30, wherein the cytokine is IL-7, IL-15, IL-21, IL-22 or IL-33; or a fragment thereof.

32. The anti-albumin construct of claim 30 or 31, wherein the cytokine is IL-7, IL-15 or IL-21; or a fragment thereof.

33. An anti-albumin construct according to any one of claims 30 to 32, wherein the cytokine is IL-7.

34. An anti-albumin construct according to any one of claims 30 to 32, wherein the cytokine is IL-15.

35. The anti-albumin construct of claim 1 or 34, having the amino acids of SEQ ID NO:

101.

36. An anti-albumin construct according to any one of claims 30 to 32, wherein the cytokine is IL-21.

37. The anti-albumin construct according to claim 1 or 36, which has the amino acid sequence of SEQ ID NO: 99, 100, 149 or 150.

38. An anti-albumin construct according to any one of claims 16 to 23, wherein the second polypeptide portion comprises the amino acid sequence of a cytokine receptor or a fragment thereof.

39. The anti-albumin construct of claim 34, wherein the cytokine receptor is IL-15Rα.

40. The anti-albumin construct according to claim 1 or 39, which has the amino acid sequence of SEQ ID NO: 103 or 104.

41. A pharmaceutical composition comprising an anti-albumin construct according to any one of claims 1 to 40 and a pharmaceutically acceptable excipient.

42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is in a single dosage form.

43. The pharmaceutical composition of claim 41 or 42, wherein the pharmaceutical composition is a solid.

44. The pharmaceutical composition of claim 41 or 42, wherein the pharmaceutical composition is a parenteral dosage form.

45. The pharmaceutical composition of claim 44, wherein the pharmaceutical composition is an intravenous dosage form.

46. ​​The pharmaceutical composition of any one of claims 41, 42, 44 and 45, wherein the pharmaceutical composition is a solution.

47. Use of an anti-albumin construct according to any one of claims 1 to 40 or a pharmaceutical composition according to any one of claims 41 to 46 in the preparation of a medicament for treating, preventing or alleviating one or more symptoms of cancer in a subject.

48. The use according to claim 47, wherein the cancer is gastric cancer or lung squamous cell carcinoma.

49. Use according to claim 47 or 48, wherein the subject is a human.

Citation Information

Patent Citations

  • Generation of heavy-chain only antibodies in transgenic animals

    US20090307787A1

  • H-Chain-only antibodies

    US20100122358A1

  • Binding molecules

    US20110118444A1

  • Soluble heavy-chain only antibodies

    US20130323235A1

  • Binding molecules

    US20130344057A1